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ABSTRACT 
 
Depression is a common psychiatric illness, affecting over 120 million people worldwide. 
Women are affected disproportionately compared to men, and a large body of clinical evidence 
suggests a role for changes in estrogen levels in the etiology of depression. Successful selective 
serotonin reuptake inhibitor (SSRI) antidepressant treatment is frequently correlated with 
normalization of HPA axis activity. It can take several weeks to begin to see therapeutic effects 
of SSRIs; this therapeutic lag is thought to be due in part to the time it takes for desensitization 
of 5-HT1A receptor signaling in the paraventricular nucleus (PVN) of the hypothalamus to occur.  
It takes up to seven days of chronic SSRI treatment to desensitize 5-HT1AR signaling, but 
this effect is accelerated by estradiol (EB) treatment. Understanding estradiol modulation of 5-
HT1AR signaling will be important for the development of improved SSRI therapy for the 
treatment of depression. The purpose of this dissertation therefore was to identify the 
mechanisms underlying EB-induced desensitization of 5-HT1AR signaling. To test the hypothesis 
that signaling through GPR30 is necessary for EB-induced desensitization of 5-HT1AR signaling, 
GPR30 protein expression in the PVN was knocked down via adenoviral vector delivery of 
siRNA against GPR30. Reduction of GPR30 protein expression prevented EB-induced 
desensitization of 5-HT1AR signaling. To test whether stimulation of GPR30 is sufficient for 
desensitization of 5-HT1AR signaling, rats were treated for two days with systemic injections of 
the selective GPR30 agonist G-1 or EB. G-1 and EB treatment both reduced the hormone 
responses to 5-HT1AR stimulation. 
To investigate the effects of GPR30 stimulation on 5-HT1AR signaling at the molecular 
level, changes in protein and mRNA levels of 5-HT1AR, Gαz, GPR30, and RGSz1 were 
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examined after EB and G-1 treatment. EB treatment produced a decrease in 5-HT1AR protein, 
while both EB and G-1 treatment increased RGSz1 mRNA and altered expression of several 
RGSz1 proteins, leading to the hypothesis that alteration in RGSz1 expression and 
posttranslational modification underlies estradiol-induced desensitization of 5-HT1AR signaling. 
In particular, EB and G-1 treatment increased localization of sumoylated and glycosylated 
RGSz1 in the detergent resistant microdomain of the plasma membrane, where it could 
physically interact with and inactivate Gαz protein. The effects of GPR30 signaling, such as a 
decrease in 5-HT1AR protein and increase of RGSz1 isoforms, on the 5-HT1AR signaling 
pathway are not seen after SSRI treatment, suggesting a mechanism by which estradiol acts 
separately and synergistically with SSRIs to accelerate desensitization of 5-HT1AR signaling. 
Improving the therapeutic efficacy of SSRIs through selective targeting of GPR30 and RGSz1 
could have important clinical relevance for the treatment of depression. 
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CHAPTER ONE: INTRODUCTION 
 
DEPRESSION  
 Depression, clinically known as Major Depressive Disorder, is one of the most common 
psychiatric illnesses, with a lifetime prevalence of greater than 17% in the general population 
(Anxiety and Depression Association of America). Depression is characterized by depressed 
mood, a loss of interest or pleasure in daily activities, impaired function in everyday life, fatigue 
or loss of energy, feelings of guilt and worthlessness, poor concentration, and changes in sleep, 
appetite, or weight (DSM-IV). Because depression can lead to substantial impairment of daily 
functions, it is a leading cause of disability worldwide. Fortunately, depression can be reliably 
diagnosed in primary care, and there are many pharmacotherapeutic treatments available. 
Sex differences in depression 
 The prevalence of depression in women is twice as high as in men, although this higher 
rate is not constant across the lifespan: during childhood or advanced old age, there is little 
difference in rates of depression between males and females, but this difference increases 
towards mid-life in women without changing in men
1-4
. Some studies have found that women 
also experience longer depressive episodes than men, although this finding is not consistent. 
Women are more prone to depression during times of ovarian hormone fluctuation, such as 
puberty, the postpartum period, the premenstrual phase of the menstrual cycle, and 
perimenopause
1,5-7
. Because the increase in onset of depression in women corresponds to the 
female reproductive life, it has been hypothesized that alterations in ovarian sex steroids, 
particularly estrogens, during childbearing years may contribute to the higher rate of mood 
disorders in women
8
.  
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Treatments of depression 
Serotonergic modulators 
Serotonin dysfunction has been implicated in the etiology of depression
9-14
. Serotonin 
neurotransmission is a balance of several processes: synthesis, reuptake, degradation, transmitter 
release, and receptor activation. Synthesis is a two-step process of converting the amino acid 
tryptophan to 5-hydroxytryptamine (5-HT), governed by the rate-limiting enzyme tryptophan 
hydroxylase (TPH). Free serotonin that has not been packaged into vesicles is degraded by 
monoamine oxidase A (MAO-A), but most of the synaptic clearance is accomplished by the 
serotonin transporter (SERT, also called 5-HTT). Treatments for depression that modulate 
serotonin transmission target these processes. 
 Antidepressant drugs are classified as first or second generation pharmacotherapeutics. 
First generation drugs include MAO inhibitors (MAOIs) and tricyclic antidepressants (TCAs). 
The oldest antidepressants, MAOIs, prevent MAO degradation of serotonin, norepinephrine, and 
dopamine, thus increasing the amount of neurotransmitter available for release. The first MAOIs 
were irreversible; newer MAOIs are reversible and can be selective for MAO-A, which 
preferentially deaminates serotonin, norepinephrine, and epinephrine with fewer side effects than 
the older drugs. MAOIs often work well for patients who are treatment-resistant; however, 
concerns over potentially lethal dietary and drug interactions have limited clinical MAOI use. 
Recent research suggests that these concerns may be based largely on misinformation and 
outdated research, and the potential use of these drugs for treatment of depressed should be 
reexamined
15
. 
 TCAs, named for the characteristic three-ring structure shared by compounds in this 
class, are highly effective antidepressants that bind to presynaptic transporters to inhibit 
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neurotransmitter reuptake. Many drugs of this class are equally effective at inhibiting both 
norepinephrine and serotonin reuptake, though some are more effective on one transmitter than 
the other. In addition to blocking reuptake, many TCAs also block acetylcholine, histamine, and 
α-adrenergic receptors, thus contributing to their severe side effects. 
 Second generation antidepressants were designed to be more selective in their action and 
thus avoid the anticholinergic and cardiovascular effects produced by MAOIs and TCAs. 
Selective serotonin reuptake inhibitors (SSRIs) such as fluoxetine, paroxetine, and citalopram are 
the most commonly prescribed antidepressants. SSRIs are more selective than TCAs in blocking 
serotonin reuptake and although they are not much more effective, they are better tolerated. 
Selective norepinephrine/serotonin reuptake inhibitors (SNRIs) such as venlafaxine are several 
fold more selective for serotonin than norepinepherine
16
. 
Problems with current antidepressants 
One major drawback to antidepressants that modulate serotonin transmission is the risk of 
serotonin toxicity. Serotonin toxicity is a dangerous syndrome which can result from use of 
serotonergic antidepressants in combination with other serotonergic drugs or a diet high in foods 
that elevate tyramine levels. Onset of serotonin toxicity is rapid (within 24 hours) and features 
confusion, hypomania, restlessness, myoclonus, hyperreflexia, diaphoresis, shivering, tremor, 
diarrhea, or incoordination
17
. 
The two major problems with all antidepressant drugs are 1) that only approximately two 
thirds of patients respond to treatment, and 2) therapeutic efficacy requires chronic treatment that 
can take up to 12 weeks to produce
16
. In order to improve response and remission rates, other 
therapies can be used as adjuvants to SSRI treatment, such as lithium, atypical antipsychotics, 
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electroconvulsive therapy, or deep brain stimulation
18-20
. However, some of these treatments can 
be aggressive, and do not improve rates of remission
21
. 
 
SEROTONIN 
Serotonin receptors 
Serotonin is a monoamine neurotransmitter that acts on the central nervous system (CNS) 
and the peripheral nervous system (PNS), as well as in non-neuronal tissues such as the 
gastrointestinal tract, platelets, and the cardiovascular system
22
. Serotonin is synthesized from 
the amino acid tryptophan in serotonergic neurons, which are concentrated in the medulla, pons, 
and the dorsal and medial raphe nuclei of the midbrain. Serotonergic neurons project to almost 
every area of the forebrain, including the cerebral cortex, hippocampus, limbic system, and 
hypothalamus. Because of its wide distribution, serotonin has important roles in many 
physiological functions, including sleep, feeding, sexual behavior, and thermoregulation, and has 
been implicated in pathological states, such as mood disorders, anxiety disorders, and 
psychosis
22
.  
 Serotonin produces its effects through a large and diverse family of membrane-bound 
receptors. The serotonin receptor family is one of the largest and most complex neurotransmitter 
receptor families, containing 7 different subfamilies (5-HT1R - 5-HT7R) and at least 14 distinct 
members
23,24
. The different receptor subtypes are classified according to pharmacological 
characteristics, intracellular signal transduction mechanisms, and structural characteristics
22,25
. 
The majority of 5-HT receptors are metabotropic G protein coupled receptors (GPCRs). GPCRs 
couple to heterotrimeric G proteins; upon stimulation of the receptor with a ligand or agonist, the 
GDP molecule bound to the Gα subunit exchanges with GTP, thus activating the G protein. 
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Activated GTP-Gα then dissociates from the Gβγ protein subunit, leaving both free to activate 
downstream effectors. Hydrolysis of GTP-Gα to GDP-Gα resets the signaling system.  
 The 5-HT1R subfamily members preferentially couple to the Gi/o family of inhibitory G 
proteins to inhibit adenylyl cyclase (AC) and reduce cAMP production and protein kinase A 
(PKA) activation. This family includes 5 members: 5-HT1A, 5-HT1B, 5-HT1D, 5-ht1e (putative), 
and 5-HT1F. The 5-HT2R subfamily contains 3 members, 5-HT2A, 5-HT2B, and 5-HT2C, all 
coupled to the Gq/11 signaling system to stimulate the phospholipase C (PLC) signaling cascade 
and increase intracellular calcium signaling
22,26
. 
5-HT3R is the only ionotropic (ligand-gated ion channel) 5-HT receptor subtype. 5-HT3 
receptors are non-selective cation channels, which produce a rapid excitatory response in 
neurons due to influx of Na
+
 and Ca
+
, and efflux of K
+
. Functional channels may be 
homopentameric, consisting of five 5-HT3AR subunits, or heteropentameric, a mixture of 5-
HT3AR subunits plus 5-HT3B, 3C, 3D, or 3E subunits
27,28
.  
 5-HT4, 5-HT6, and 5-HT7 receptors all preferentially couple to Gαs proteins to activate 
AC and increase cAMP production and protein kinase A (PKA) activation. 5-HT4Rs have a wide 
distribution outside of the CNS, being found in the heart, intestine, bladder, and kidney. 5-HT7Rs 
are expressed in the hypothalamus, hippocampus, cerebral cortex, amygdala, and dorsal 
raphe
29,30
, and play an important role in the control of circadian rhythms, thermoregulation, and 
learning and memory
31
.  
 The 5-HT5R subfamily (A and B) remains largely undescribed, although current evidence 
suggests coupling to Gi/o and inhibition of AC, similar to 5-HT1 receptors
32,33
. Recent work has 
shown that 5-HT5AR maintains 5-HT currents in the absence of 5-HT1AR and 5-HT2R signaling 
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in the prefrontal cortex, via coupling to inward rectifying K
+
 channels (GIRKs)
34
, and thus may 
serve as a compensatory, biological safeguard. 
5-HT1A Receptor  
Distribution and physiological roles 
5-HT1ARs are distributed throughout the CNS, both pre- and post-synaptically. In the 
dorsal and medial raphe nuclei, 5-HT1ARs are somatodendritic autoreceptors; activation of 
autoreceptors produces a hyperpolarizing current via coupling to GIRKs to inhibit neuronal 
firing and reduce 5-HT release, thus providing rapid negative feedback for 5-HT signaling.  
Postsynaptic 5-HT1ARs are located on non-serotonergic neurons such as GABAergic
35,36
 and 
cholinergic
37
 neurons, and are therefore also known as heteroreceptors. Heteroreceptors are 
widely distributed in the cortex and limbic systems, particularly the hippocampus, and including 
the entorhinal cortex, frontal cortex, amygdala, and hypothalamus
24
.  
5-HT1AR has a wide variety of functions in the mammalian brain, including regulation of 
post-synaptic activity, synaptic plasticity, neurogenesis, neuroprotection, and learning and 
memory
24
. Selective stimulation of postsynaptic 5-HT1AR with (+)8-Hydroxy-2-
dipropylaminotetralin ((+)8-OH-DPAT) induces the 5-HT behavioral syndrome, which includes 
hyperphagia, hypothermia, altered sexual behavior, and tail flick response
38-40
. 5-HT1AR also 
plays a significant role in the regulation of mood-related behaviors, particularly depression. 
Administration of 5-HT1AR agonists reduces depressive behaviors in the forced swim test
41,42
 
and tail suspension test, and 5-HT1AR knockout mice show antidepressant-like behavioral 
phenotypes 
43-45
. 
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Receptor structure and signal transduction 
 The human 5-HT1AR gene Ht1a is located on chromosome 5q11.2-q13
22
. Rat Ht1a is an 
intronless gene that codes for 422 amino acids, and shares 89% homology with the human 
receptor. 5-HT1AR protein has a 7-transmembrane structure and is localized to the plasma 
membrane
25
. Canonical 5-HT1AR signaling is mediated via coupling to inhibitory G proteins 
(Gαi1, Gαi2, Gαi3, Gαo)
46
, as inhibition of AC and PKA activity via 5-HT1AR signaling has 
been shown to mediate 5-HT1AR regulated behaviors
47
.  
 Coupling to G proteins is brain region specific: in the dorsal raphe nucleus (DRN), 5-
HT1AR preferentially couples to Gαi3; in the hippocampus, 5-HT1AR couples to Gαo
48
. In the 
hypothalamus, 5-HT1AR can couple to the G protein Gαz
49
. Unlike other members of the Gαi 
protein family, Gαz lacks the cysteine residue in the C terminus that serves as the substrate for 
bordatella pertussis toxin (PTX) catalyzed ADP ribosylation
50
, making Gαz the only Gi/o family 
member known to be insensitive to PTX inhibition. 
 5-HT1AR signaling has been shown to activate a variety of signal transduction cascades 
beyond the canonical pathways. Activation of the mitogen activated protein kinase (MAPK) 
family member extracellular signal-regulated kinase (ERK) via phosphorylation is affected by 5-
HT1ARs. Phosphorylation of proteins by ERK in neurons results in receptor and ion channel 
activation, gene expression, and neuroplasticity
51
. One target of ERK is cAMP-responsive 
element binding protein (CREB), a well-known transcription factor which has been linked to 
stress, anxiety, and depression
52
. The effect of 5-HT1AR on ERK phosphorylation varies in cells 
of neuronal origin
24
. In the hippocampus, 5-HT1AR activation decreases ERK phosphorylation
53-
55
, and differentiated raphe neurons show decreased ERK activity via Gβγ subunit signaling
56
. In 
acute prefrontal cortical slices, only simultaneous activation of both 5-HT1A and N-methyl-D-
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aspartate (NMDA) receptors decreases ERK phosphorylation
57
. In the hypothalamus, 5-HT1AR 
agonists rapidly but transiently increase phosphorylation of ERK
53,55,58,59
. 
 There is also evidence of cross-talk between 5-HT1AR signaling and growth factor 
signaling via tyrosine kinase receptors, phosphotidylinositol 3-kinase (PI3K), and subsequent 
activation of Akt. Akt is involved in mediation of neurotrophin and neurotransmitter actions
60,61
; 
a major target of Akt is glycogen synthase kinase 3 (GSK3), which has been implicated in mood 
disorders
24,62,63
. In neuronal cells, 5-HT1AR agonists increase Akt activation in a PI3K-dependent 
manner, and this effect is sensitive to PTX
64
. 
Regulation of G protein signaling 
 GPCRs initiate and maintain signaling by catalyzing GDP dissociation from and GTP 
binding to Gα subunits; signal amplitude is therefore a balance between GTP binding and 
hydrolysis. GTP hydrolysis can be accelerated by GTPase-activating proteins (GAPs). GAPs can 
thus decrease signal amplitude, terminate a signal, or suppress basal signal amplitude in the 
absence of stimulation. Regulators of G protein signaling (RGS) proteins are the most numerous 
family of GAPs, catalyzing the hydrolysis of the Gαq and Gαi/o families
65-67
. 
 RGS proteins are grouped into four distinct subfamilies based on sequence homology: the 
R4 family (RGS1, RGS2, RGS3, RGS4, RGS5, RGS8, RGS13, RGS16), R7 (RGS6, RGS7, 
RGS9, RGS11), R12 (RGS10, RGS12, RGS14), and Rz (RGSz1, RGSz2, RET-RGS1, and 
GAIP). RGS proteins contain a conserved domain of about 130 amino acids, called the RGS box, 
which binds the GTP-Gα subunits and accelerates hydrolysis. In addition, most RGS proteins 
also contain other domains flanking the RGS box that allow for interaction with regulatory 
elements and localization. For example, RGS1, RGS2, RGS4, and RGS16 have an amphipathic 
helix at the N-terminus of the RGS box that could serve as a membrane anchor, the R7 family 
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possesses G protein gamma subunit like (GGL) and disheveled, Egl-10 and Pleckstrin (DEP) 
domains, RGS12 contains a phosphotyrosine-binding (PTB) domain, as well as a PDZ domain. 
A conserved cysteine string motif in RGS4, RGS16, and GAIP is known to be palmitoylated, 
which affects RGS targeting to the membrane and intracellular trafficking
67-71
. These RGS box 
flanking regions, conserved among subfamilies, allow for physiological functions in addition to 
negative regulation of G protein signaling, such as kinetic scaffolds
72
, guanine nucleotide 
exchange factors
73,74
, ion channel modulators
75
, and cellular signal integration
76
.  
 The Gαi/o and Gαs families of G proteins have an intrinsic rate of hydrolysis of bound 
GTP with a half-time of about 10-20 seconds. Gαz, although classified as belonging to the Gαi/o 
family, shares only about 66% homology with this family’s other members and has an extremely 
low rate of hydrolysis, with a half-time of around 7 minutes
50,77
, indicating that Gαz signaling is 
difficult to switch off. Gαz has a limited pattern of tissue expression, being found mainly in the 
brain, retina, platelets, and adrenal medulla, in contrast to the more ubiquitous Gαi/o 
proteins
50,78
. RGSz1 is a selective GAP for Gαz that is found almost exclusively in the brain, and 
accelerates the rate of GTP hydrolysis by 200- to 400-fold, thus reducing the half-time to 
seconds and effectively regulating Gαz downstream signaling
79,80
.  
 
HYPOTHALAMIC PITUITARY ADRENAL AXIS 
Physiological function 
 Serotonin signaling, especially 5-HT1AR, is an important mediator of the hypothalamic-
pituitary-adrenal (HPA) axis. The HPA axis is the final common pathway of the stress response. 
HPA axis neuroendocrine activity is governed by secretion of corticotrophin releasing factor 
(CRF) from the paraventricular nucleus (PVN) of the hypothalamus, which activates release of 
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adrenocorticotrophic hormone (ACTH) from the anterior pituitary; ACTH in turn stimulates 
secretion of glucocorticoids (cortisol in humans, corticosterone in rodents) from the adrenal 
cortex
81,82
.  
In addition to regulating peripheral functions such as metabolism and immunity, the HPA 
axis has significant effects on the brain. Glucocorticoids are major stress hormones that bind to 
two types of receptors: mineralocorticoid receptors (MR) and glucocorticoids receptors (GR). 
MRs and GRs are distributed throughout the brain, particularly in regions that play a role in 
cognitive and neuroendocrine function, such as the hippocampus, amygdala, and prefrontal 
cortex
83
. MRs and GRs also serve as potent negative feedback regulators for the HPA axis at the 
level of CRF and ACTH synthesis and release in the PVN and pituitary, respectively
84
. 
Hyperactivity in depression 
 Although the main role of the HPA axis is to maintain homeostasis under stress, long-
term activation can be harmful to the body. Abnormal HPA activity underlies many psychiatric 
disorders, including depression
85
. The most consistent biomarkers in depressed patients show 
increased HPA activity, such as high levels of plasma CRF and ACTH, decreased CRF receptors 
in the PVN, and increased salivary cortisol
85-88
, as well as pituitary and adrenal hypertrophy
89,90
. 
Stressful early life events (such as maternal separation or child abuse) and even prenatal stressors 
(such as maternal smoking) are linked to HPA axis hyperactivity and increased risk for 
depression and anxiety disorders
85
. Successful antidepressant treatment is frequently correlated 
with normalization of HPA axis activity. 
Mediation by serotonin 
Serotonin is a major mediator of the HPA axis
81,91
. Stimulation of the HPA axis by acute 
administration of an SSRI or a non-selective serotonin agonist increases plasma ACTH and 
 23 
corticosterone through involvement of 5-HT1AR and 5-HT2A/CR
92-96
. Selective stimulation of 5-
HT1AR with (+)8-OH-DPAT produces an increase in the plasma levels of oxytocin, ACTH, and 
corticosterone, which can be prevented by treatment with the 5-HT1AR antagonist WAY 100, 
635
97
, suggesting a particular role for postsynaptic 5-HT1AR in HPA axis function. Furthermore, 
treatment with PTX has no effect on OT and ACTH release, demonstrating that 5-HT1AR 
mediation of these hormones is accomplished via signaling through the PTX-insensitive Gαz 
subunit
49
. Although OT is not part of the HPA axis, it is released upon stimulation with (+)8-
OH-DPAT and can therefore serve as a direct marker of 5-HT1AR function in the PVN. 
 
DESENSITIZATION OF 5-HT1AR SIGNALING 
Therapeutic lag in SSRI treatment  
Multiple lines of evidence have led to the hypothesis that improved serotonin 
neurotransmission underlies the therapeutic effect of antidepressants
98
. To achieve clinical 
efficacy, chronic use of SSRIs (3-12 weeks) is required
21,99,100
. The mechanism of action 
underlying SSRI therapeutic efficacy is not clearly understood, but the therapeutic lag suggests 
that functional, neuroadaptive changes are necessary. SSRIs target and block the presynaptic 5-
HT transporter, thus preventing 5-HT clearance from synapse and prolonging 5-HT effects on 
both autoreceptors and postsynaptic receptors. Acutely, SSRI-induced increased stimulation of 5-
HT1A autoreceptors in the DRN produces a transient increase in feedback regulation, followed by 
desensitization of the autoreceptors and subsequent increased serotonin transmission and HPA 
axis activity, which may contribute to the therapeutic lag
101-103
. 
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ESTROGEN 
Physiological roles 
 Estrogens are involved in the regulation of affective states, and both clinical and 
experimental evidence implicates estrogen levels with the etiology of depression. Naturally-
occurring estrogens are a group of biologically-active steroidal hormones
104
. Estrogens in 
mammals regulate a number of physiological processes, such as reproduction, cardiovascular 
protection, bone integrity, and cellular homeostasis
105
. Estrogens are both neuroactive steroids, in 
that they are synthesized by an endocrine gland and secreted into the blood, and neurosteroids, in 
that they can be synthesized locally in the brain via aromatization of androgen precursors or de 
novo from cholesterol. It has been hypothesized that neuroactive estrogens are responsible for the 
classical genomic effects of estradiol, while brain-synthesized estrogens are the source of rapid 
estrogen effects in the brain
106-108
.  
Both clinical and experimental studies have shown that 17β-estradiol (E2, the major 
circulating estrogen) has numerous effects on the brain throughout the lifespan, including sexual 
differentiation during development, mood, locomotor activity, pain sensitivity, memory and 
attentional mechanisms, and is protective against neurodegeneration and brain injury
109,110
. 
Estradiol has been found to have neurotrophic, anti-apoptotic, and anti-inflammatory actions, all 
of which may contribute to its neuroprotective effects
109
. 
Estrogen receptors 
Nuclear receptors 
 The hydrophobic steroid structure of estradiol allows it to easily pass through the plasma 
membrane, and historically most of the focus on estradiol signaling has been on intracellular 
estrogen receptors (ERs). There are two intracellular ERs, ERα and ERβ. These receptors are 
 25 
encoded by two distinct genes, ESR1 and ESR2, respectively. ERα and ERβ share significant 
sequence homology, especially in their DNA and ligand binding domains (96% and 56%, 
respectively)
111
. Both are classical steroid nuclear receptors which, upon ligand binding, 
dimerize and localize in the nucleus where they bind to estrogen response elements (EREs) on 
DNA to regulate transcription
112
. ERα and ERβ have similar affinity for a number of estrogens 
and estrogen antagonists
113
 as well as a similar ability to regulate genes containing the ERE
114
. In 
addition, both ERs can interact with other transcription factors, such as Fos and Jun, which bind 
DNA at the AP-1 site to regulate transcription independently of EREs
115
. 
 ERα and ERβ are differentially distributed throughout the body: ERα shows high 
expression in the pituitary, kidney, and adrenal tissue, while ERβ shows moderate to high 
expression in prostate, lung, bladder, and brain. Both ERs are expressed highly in the ovary, 
testis, and uterus
113
. In the brain, ERα and ERβ expression overlap significantly, although there 
are regions where expression of one is higher than the other. ERα is highly expressed in areas 
that regulate energy homeostasis and reproductive function, such as the preoptic area and arcuate 
and ventromedial nuclei of the hypothalamus. ERβ, on the other hand, shows high mRNA and 
protein expression in regions involved in the regulation of mood and HPA axis activity, 
including the hippocampus, DRN, amygdala, cerebral cortex, hypothalamic PVN, and 
hypothalamic preoptic area
109,116-118
. ERα and ERβ immunoreactivity has been shown to vary 
across the estrous cycle
119
, and ER expression on synapses is regulated by estrogen in an age-
dependent manner: ERα labeling is decreased in young animals and unaffected in older 
animals
120
, while ERβ immunoreactivity is increased in both young and aged animals compared 
to midlife
121
. 
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Membrane receptors 
 Nongenomic, rapid estrogen actions at the plasma membrane have been known for a 
number of years
122
; however, it wasn’t until more recently that this aspect of estrogen activity 
began to be investigated. Nongenomic estrogen effects include rapid modulation of intracellular 
second messengers, such as nitric monoxide, cAMP and cGMP, activation of MAPK and PLC 
signaling pathways, activation of transcription factors such as CREB, and modulation of G 
protein coupling
109,123,124
, which are important in neuroprotection, among other processes. 
Although rapid estrogen signaling is commonly referred to as nongenomic, these effects can also 
involve local protein synthesis
125
 and the activation of signaling cascades that lead to 
transcriptional changes independent of nuclear ERs
108
. 
While emerging evidence suggests that palmitoylation of ERα may contribute to 
localization of the receptor to the plasma membrane
126
 and thus mediate nongenomic signaling, 
the majority of intracellular ERs accumulate in the nucleus
123
. Several splice variants of the 
genes encoding ERα and ERβ (ESR1 and 2, respectively) have been identified and proposed as 
membrane ERs
127
. Additionally, novel membrane ER proteins have been identified, namely Gq-
mER, ER-X, and G protein coupled receptor 30 (GPR30/GPER1). 
Gq-mER is a GPCR which preferentially couples to Gαq proteins, signaling via PLC-
PKC-PKC pathways to attenuate GABAB receptors and µ-opioid receptor activation of GIRKs in 
hypothalamic POMC neurons
128
. Gq-mER is selectively activated by STX, an analogue of 4-OH-
tamoxifen; treatment with STX has demonstrated that Gq-mER is important in the control of 
homeostatic functions, such as feeding, temperature regulation, and ovulation
127,128
 independent 
of ERα/β activation. 
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 ER-X is highly expressed in the brain, uterus, and lung, and appears to be a seven-
transmembrane receptor associated with caveolar-like microdomains which signals via the 
MAPK/ERK pathway. Interestingly, 17α-estradiol (generally considered an inactive natural 
enantiomer of 17β-estradiol) is even more potent than 17β-estradiol in activating MAPK/ERK 
through ER-X
129,130
, which sets ER-X apart from other estrogen receptors pharmacologically. 
The physiological functions of ER-X are not yet clear. ER-X expression is upregulated during 
development and declines dramatically in the adult, but is upregulated following ischemic stroke, 
suggesting that the receptor may be important for brain injury and aging in addition to 
development
129
. 
 GPR30 was originally cloned as an orphan GPCR
131
 and subsequently identified as a 
membrane ER with high and selective affinity for estrogens
132-135
. Human GPR30, also known as 
GPER, is located on chromosome 7p22.3 and is composed of 3 exons. An activator protein-1 
(AP-1) site exists in the second intron of the gene, which may be a transcriptional regulatory 
region that is activated in response to epidermal growth factor (EGF)
136
. The protein is a seven 
transmembrane receptor comprised of 375 amino acids, with an apparent molecular weight of 
about 41kD. GPR30 has been reported to localize to the plasma membrane, the endoplasmic 
reticulum and the Golgi apparatus
134,137,138
.  
GPR30 distribution and signal transduction 
Studies in GPR30 knockout mice have demonstrated that GPR30 has important roles in 
the immunological system, circulatory system, and glucose homeostasis
139
. In the brain, high 
GPR30 immunoreactivity has been observed in the isocortex, piriform and entorhinal cortex, 
hippocampus, and hypothalamus with no apparent gender differences
140,141
. GPR30 distribution 
is distinct from ERα or ERβ
141
, and colocalizes with oxytocin (OT) and CRF in the PVN and 
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supraoptic nucleus (SON) of the rat hypothalamus
134,141-143
, suggesting a role for estradiol and 
GPR30 in the release of these hormones.  
In human ER-negative SKBR3 and MCF-7 breast cancer cells, stimulation of GPR30 
with estradiol increases production of cAMP and activation of PKA via coupling to Gαs. The 
Gβγ subunit activates Src tyrosine kinase which, via matrix metalloproteinase (MMP), releases 
HB-EGF into the extracellular space to stimulate EGF receptors and activation of PI3K and 
ERK
144-146
. Interestingly, the ER antagonists tamoxifen and ICI 182, 780 act as agonists for 
GPR30; stimulation of GPR30 with tamoxifen has been shown to activate PI3K signaling 
cascade
134
. Furthermore, estradiol signaling through GPR30 can also lead to transcriptional 
effects. GPR30 signaling upregulates nerve growth factor production by inducing c-fos 
expression via cAMP in an ERE-independent manner
136,147,148
, and induces cyclin D2 and Bcl-2 
expression via PKA-mediated CREB phosphorylation
147,149
. 
Regulation of mood 
 Depression and anxiety scores have been shown to improve with administration of 
estradiol in naturally and surgically menopausal women
150,151
, and hormone replacement therapy 
(HRT, both estrogen and progesterone) improves mood in menopausal women
152
. In addition, 
augmentation of SSRI treatment with estradiol improved mood compared to those taking SSRIs 
alone
153,154
, and women taking estrogen therapy for the management of menopausal symptoms 
show a better response to SSRI treatment of depression than those taking HRT alone
155,156
. 
However, other studies have found no effect of combining estrogen therapy with SSRIs, and 
therefore estrogen therapy is not considered a first-line treatment for major depression
157-160
.  
This lack of effect could be due to the particular SSRI or estrogen compound used. In 
preclinical trials, the antidepressant effect of estrogenic compounds in animals models of 
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depression this depends on the type of estrogen tested. 17β-estradiol, ethinylestradiol, and 
estradiol benzoate all produce an antidepressant-like action in the forced swim test
161-163
, while 
diethyl-stilbestrol has no effect
161
, and combination of suboptimal doses of fluoxetine and 17β-
estradiol produced synergistic effects in the forced swim test and chronic mild stress behavioral 
assays
164
. 
Estrogen modulation of serotonin 
 Ovarian steroids are known to regulate the serotonin system of rodents and 
primates
6,165,166
 by increasing gene and protein expression of the rate-limiting enzyme in 
serotonin synthesis (TPH2), increasing transport and binding of SERT, decreasing gene and 
protein expression of 5-HT1A autoreceptors and 5-HT1AR binding and coupling to Gαi, and by 
decreasing MAO-A gene and protein expression
167-171
. 
 In non-human primates, chronic treatment with estradiol decreases 5-HT1AR mRNA and 
agonist binding in the raphe
169,172
, as well as decreasing G protein coupling. In addition, estradiol 
treatment significantly decreases MAO-A and MAO-B expression within serotonin and 
hypothalamic target neurons
6,173
, thereby increasing availability of serotonin at the postsynaptic 
receptor. Interestingly, a study in the Atlantic croaker hypothalamus found that inhibition of 
aromatase activity reduced TPH and serotonin expression, which was corrected with estradiol 
treatment, demonstrating a role for locally produced estradiol in modulation of the serotonin 
system
174
. 
Sex differences have been observed in the serotonin system, such as decreased SERT 
binding in female rodents and humans and greater stress-induced increase in female amygdalar 
serotonin levels
12,95,175
. Gonadal hormones have been implicated as modulators of serotonin 
transmission in raphe projection regions
176,177
 and therefore can affect response to stress. 
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Females in both rodent and human studies exhibit higher levels of glucocorticoids in response to 
various stressors, possibly due to gonadal hormones: androgen administration decreases indices 
of HPA axis activity (secretion of ACTH, glucocorticoids, and stress-induced c-fos in the PVN), 
while estradiol treatment has the opposite effect
103
. Furthermore, estradiol has been shown to 
increase TPH2 expression in ovariectomized rats
178
, possibly leading to increased serotonergic 
transmission.  
 Consistent findings show that both basal and stress-induced adrenal steroid secretion is 
greater in females than in males
179-181
, and estrogen replacement in ovariectomized female 
rodents can inhibit responses to stress
182-184
. Administration of 17β-estradiol to postmenopausal 
women increases circulating levels of OT and arginine vasopressin (AVP)
185
, and rapidly 
stimulates intrahypothalamic and peripheral OT release
142,186
, demonstrating direct modulation of 
the HP axes. 
Neuroendocrine challenge: a model for HPA axis hyperactivity and therapeutic lag  
HPA axis hyperactivity is an important biological marker for depression. Neuroendocrine 
challenge studies in both humans and rodents have shown that chronic antidepressant treatment 
produces desensitization of postsynaptic 5-HT1AR signaling, as evidenced by decreased OT and 
ACTH release in response to 5-HT1AR agonists
187-189
. In rats, neuroendocrine challenge with the 
5-HT1AR selective agonist 8-OH-DPAT increases OT and ACTH release; the increase in ACTH 
levels is similar to the HPA axis hyperactivity seen in depression. Desensitization of the 
hormone response to 8-OH-DPAT by SSRIs takes 7-14 days
189-191
, thus modeling the 
antidepressant therapeutic lag and demonstrating that desensitization of postsynaptic 5-HT1AR 
signaling in the PVN is required for SSRI efficacy. We can therefore use OT and ACTH levels 
after 5-HT1AR stimulation as peripheral markers for HPA activity and to examine the functional 
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impact of GPR30-mediated estradiol signaling on 5-HT1AR signaling. Understanding the 
interaction between GPR30-mediated estradiol signaling and 5-HT1AR signaling will be 
important for the development of novel targets for the acceleration of treatment of depression.  
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CHAPTER TWO 
 
STATEMENT OF PURPOSE 
 Mood disorders are more prevalent in women
2,192
, suggesting a gender-dependent risk 
factor for mood disorder development. Estrogen treatment has been shown to alleviate symptoms 
of mood disorders in women, especially when used in conjunction with SSRI treatment
193-196
. 
Serotonin signaling influences mood disorders, such as depression, anxiety, premenstrual 
dysphoric disorder, and post-menopausal and postpartum depression
197-199
. 5-HT1ARs in the PVN 
are involved in HPA axis function, which has been found to be abnormal in mood disorders such 
as depression
90
; successful antidepressant treatment is associated with normalization of HPA axis 
function
84
. SSRIs are the most widely prescribed class of drug for the treatment of mood 
disorders. It takes 3-12 weeks to achieve clinical efficacy with SSRIs
200
; this therapeutic lag is 
thought to be in part due to the time it takes for desensitization of the 5-HT1AR signaling in the 
PVN of the hypothalamus to occur
201-203
. Thus, acceleration of the desensitization of 5-HT1AR 
signaling in the PVN may reduce the therapeutic lag of SSRIs. 
 In the rat PVN, it takes seven days of SSRI treatment to show full desensitization of 5-
HT1AR signaling
189,204
, as demonstrated by a lack of OT and ACTH hormone release in response 
to 5-HT1AR stimulation. Our laboratory has demonstrated that a physiologically active estrogen, 
17β-estradiol 3-benzoate (EB), alone is capable of inducing a partial desensitization of 5-HT1AR 
signaling in the PVN of rats within two days
204,205
. Furthermore, we have shown that combining 
EB with the SSRI fluoxetine results in full desensitization of 5-HT1AR signaling in just two 
days
206
. Therefore, combining EB treatment with SSRIs to accelerate desensitization of 5-HT1AR 
signaling may have clinical relevance to decrease therapeutic lag. However, because estrogen 
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therapy is associated with increased risk of breast cancer, stroke, and heart disease
207-209
, 
identifying the estrogen receptor and associated changes in 5-HT1AR signaling components that 
contribute to desensitization will suggest new targets to accelerate the onset of SSRI therapeutic 
effects. 
 Previous work in our laboratory has shown that one day of EB treatment is not enough to 
induce 5-HT1AR signaling desensitization, suggesting that genomic effects are involved
205
. There 
are two known nuclear estrogen receptors, which upon binding estradiol, dimerize and 
translocate to the nucleus where they bind EREs on DNA to regulate transcription. In the PVN, 
ERα density is low, while density of ERβ is much higher, especially in OT neurons
165,210-212
. 
However, recent work in our laboratory has shown that an ERβ selective agonist DPN did not 
mimic the effect of EB on 5-HT1AR signaling, and siRNA knockdown of ERβ did not prevent 
EB-induced desensitization of 5-HT1AR signaling. It is therefore unlikely that ERβ is involved in 
this mechanism
213
. 
 The non-classical membrane estrogen receptor, GPR30, is expressed in the PVN and 
colocalizes with 5-HT1AR, OT, and CRF in the PVN
140,143,214
. Intra-PVN treatment with the 
selective GPR30 agonist G-1 decreased 5-HT1AR signaling similar to EB, and inhibition of 
GPR30 βγ signaling by PTX treatment abolished the EB-induced desensitization response
143
. 
These data suggest that signaling through GPR30 is involved in the EB-induced desensitization 
of 5-HT1AR signaling.  
 The purpose of this study is to identify the mechanisms responsible for estradiol-induced 
desensitization of 5-HT1AR signaling, and to answer two questions. First, which estrogen 
receptor is responsible for the effects of EB on 5-HT1AR signaling? And second, what are the 
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estradiol-induced changes in the 5-HT1AR signaling pathway that lead to the desensitization 
response? 
 To answer the first question, we proposed the hypothesis that signaling through GPR30 
is necessary and sufficient for EB-induced desensitization of 5-HT1AR signaling. To test 
whether GPR30 is sufficient, we pretreated ovariectomized (OVX) Sprague-Dawley rats with the 
selective GPR30 agonist G-1, with systemic s.c. injections of 2.5 and 5mg/kg for two days, then 
challenged with the selective 5-HT1AR agonist (+)8-OH-DPAT and examined the hormone 
response. To test whether GPR30 signaling is necessary, we developed a recombinant adenovirus 
containing siRNA against GPR30, injected it directly into the PVN of OVX rats, and then 
evaluated the effects of EB treatment on hormone response 
 5-HT1AR is a G-protein-coupled receptor that couples to the Gi/o family of inhibitory G 
proteins
215,216
. In the PVN, OT and ACTH release is mediated via 5-HT1AR coupling to Gαz
49
. 
Gαz is active in the GTP-bound form and has a very slow intrinsic rate of GTP hydrolysis. 
RGSz1, a regulator of G protein signaling, has a high affinity for Gαz and increases the rate of 
GTP hydrolysis by over 400-fold, effectively down-regulating Gαz downstream signaling
79,80,217
. 
The predicted molecular weight of RGSz1 is 27-29kD. However, in the brain RGSz1 displays 
protein isoforms of many different sizes, which may represent different posttranslational 
modifications
73,218
. We have shown previously that two day treatment with EB resulted in an 
increase in RGSz1 mRNA, as well as RGSz1 proteins
219,220
. Changes in posttranslational 
modification of RGSz1 could affect RGSz1 interaction with and ability to regulate Gαz, thus 
contributing to desensitization of 5-HT1AR signaling. 
To address our second question (what are the estradiol-induced changes in the 5-HT1AR 
signaling pathway that lead to the desensitization response?) we used tissue from the above 
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experiments and investigated EB and G-1 induced changes in mRNA and protein levels of 
components of the 5-HT1AR signaling pathway, including 5-HT1AR, Gαz, and RGSz1, which led 
to our second hypothesis: that alteration in RGSz1 expression and posttranslational 
modification underlies estradiol-induced desensitization of 5-HT1AR signaling.  
To explore this hypothesis, we examined and characterized the different RGSz1 protein 
isoforms in the brain, including identifying the different posttranslational modifications and 
subcellular localization. Finally, we propose a mechanism by which EB signaling through 
GPR30 impacts the 5-HT1AR signaling pathway to produce desensitization of the hormone 
response to 5-HT1AR stimulation. Understanding the estrogen-receptor-mediated mechanisms 
that result in rapid desensitization of 5-HT1AR signaling will suggest novel targets for the 
improved treatment of depression and other mood disorders.  
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CHAPTER THREE 
 
GPR30 IS NECESSARY FOR ESTRADIOL-INDUCED DESENSITIZATION OF 5-HT1A 
RECEPTOR SIGNALING IN THE PARAVENTRICULAR NUCLEUS OF THE RAT 
HYPOTHALAMUS 
 
(Published in Psychoneuroendocrinol. 2012; 37, 1248-1260) 
 
ABSTRACT 
Estrogen therapy used in combination with SSRI treatment improves SSRI efficacy for the 
treatment of mood disorder. Desensitization of 5-HT1A receptors takes one to two weeks to 
develop in animals and is necessary for SSRI therapeutic efficacy. Estradiol modifies 5-HT1A 
receptor signaling and induces a partial desensitization in the paraventricular nucleus (PVN) of 
the rat within two days, but the mechanisms underlying this effect are currently unknown. The 
purpose of this study was to identify the estrogen receptor necessary for estradiol-induced 5-
HT1A receptor desensitization. We previously showed that estrogen receptor β is not necessary 
for 5-HT1A receptor desensitization and that selective activation of estrogen receptor GPR30 
mimics the effects of estradiol in rat PVN. Here, we used a recombinant adenovirus containing 
GPR30 siRNAs to decrease GPR30 expression in the PVN. Reduction of GPR30 prevented 
estradiol-induced desensitization of 5-HT1A receptor as measured by hormonal responses to the 
selective 5-HT1A receptor agonist, (+)8-OH-DPAT. To determine the possible mechanisms 
underlying these effects, we investigated protein and mRNA levels of 5-HT1A receptor signaling 
components including 5-HT1A receptor, Gαz, and RGSz1. We found that two days of estradiol 
increased protein and mRNA expression of RGSz1, and decreased 5-HT1A receptor protein but 
increased 5-HT1A mRNA; GPR30 knockdown prevented the estradiol-induced changes in 5-
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HT1A receptor protein in the PVN. Taken together, these data demonstrate that GPR30 is 
necessary for estradiol-induced changes in the 5-HT1A receptor signaling pathway and 
desensitization of 5-HT1A receptor signaling.  
 
INTRODUCTION 
Women in peri- to post-menopausal states experience a fluctuation, then decline, in 
estrogen levels
221
. The greatest reduction of estrogen levels is observed during the late 
menopausal transition and the first year post-menopause
222-224
. Decreased levels of estrogens are 
associated with various neuropsychiatric disorders such as depression, anxiety, and panic 
disorders in women
225
. During peri-menopause, there is a higher incidence of first onset of mood 
disturbances
226,227
. Change in serotonergic function, particularly 5-HT1A receptor function
6,228,229
, 
is a hallmark of such disorders
177,230-233
.  
SSRIs are commonly used to treat mood disorders. Desensitization (attenuation) of both 
somatodendritic 5-HT1A autoreceptor signaling in the midbrain and postsynaptic 5-HT1A receptor 
signaling in the PVN region of the hypothalamus are thought to contribute to the therapeutic 
efficacy of SSRIs
101,188,201,234,235
, which can take three to 12 weeks to achieve
21
. Desensitization 
of 5-HT1A receptor signaling in the PVN can be measured by neuroendocrine challenge tests that 
detect changes in OT and ACTH levels in response to 5-HT1A receptor agonists
190,236
. In humans, 
chronic treatment with SSRIs reduces the release of OT and ACTH in response to 5-HT1A 
receptor stimulation, thus demonstrating desensitization of the receptor signaling
188
. Estrogens 
have been shown to enhance the efficacy of SSRIs for the treatment of mood disorders and hot 
flushes in women
237,238
. In rats, SSRIs produce full desensitization of 5-HT1A receptor signaling 
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in PVN in seven to 14 days
189,191
, while estradiol alone can produce a partial desensitization with 
two days of treatment
204
.  
 In order to improve current therapies for mood disorders, it is important to understand 
which estrogen receptor is involved in the regulation of 5-HT1A receptors in the PVN. Of the two 
classical nuclear estrogen receptors (ERs) α and β, density of ERβ is higher than ERα in the 
PVN, especially in OT neurons
165,210,211,239
. Recent work in our laboratory has shown that ERβ is 
not involved in 5-HT1A receptor desensitization
213
. This result, together with the low expression 
of ERα in the PVN, led us to investigate the non-classical, membrane estrogen receptor GPR30. 
GPR30 binds estrogen with high affinity
134,135
, is expressed in the PVN, and colocalizes with 5-
HT1A receptors, OT, and CRF in the PVN
140,143,214
. Previous work in our laboratory showed that 
treatment with the GPR30-selective agonist G-1 decreases 5-HT1A receptor signaling, similar to 
estradiol
143
. These data suggest a role for GPR30 in the estradiol-mediated desensitization of 5-
HT1A receptor signaling in the PVN. 
The 5-HT1A receptor is known to couple to the pertussis toxin-insensitive G protein 
subunit Gαz
215,216
. Stimulation of 5-HT1A receptors in the hypothalamus stimulates release of OT 
and ACTH via coupling to Gαz
49
. RGSz1, one of six splice variants of RGS20, is a highly 
selective GAP for Gαz. It is exclusively found in the brain, where it accelerates hydrolysis of 
Gαz-bound GTP over 400-fold, with a Km of 2nM
79,80,217
. Two day treatment with estradiol 
produces a dose-dependent upregulation of RGSz1 in the PVN, without changing Gαz levels, 
that parallels the decreased hormone response induced by estradiol
219
, suggesting that RGSz1 is 
important in estradiol-induced desensitization of 5-HT1A signaling. 
 In this study, we investigated the hypothesis that GPR30 expression in the PVN is 
necessary for the estradiol-induced desensitization of 5-HT1A receptor signaling. To test this 
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hypothesis, we injected a recombinant adenovirus containing a small interference RNA (siRNA) 
against GPR30 into the rat PVN and then evaluated the effects of estradiol on 5-HT1A receptor 
signaling, as well as changes in mRNA and proteins involved in 5-HT1A receptor signaling, 
including the 5-HT1A receptor, Gαz, and RGSz1. 
 
MATERIALS AND METHODS 
Animals 
Female Sprague-Dawley (SD) rats (225-250g) from Harlan (Haslett, MI) were housed two per 
cage in a temperature-, humidity-, and light-controlled room (12h light/dark cycle). Food and 
water were available ad libitum. All procedures were conducted in accordance with the National 
Institutes of Health Guide for the Care and Use of Laboratory Animals and as approved by the 
University of Kansas Institutional Animal Care and Use Committee. All efforts were made to 
minimize animal discomfort and to reduce the number of animals used.  
 
Drugs 
17β-Estradiol-3-benzoate (EB) was purchased from Sigma-Aldrich (St. Louis, MO). EB was first 
dissolved in 100% ethanol to a concentration of 1mg/ml and then diluted with sesame oil to a 
concentration of 25µg/ml. The EB solution and sesame oil were administered at 0.4 ml/kg (EB 
dose 10µg/kg, subcutaneous (s.c.)). (+)8-Hydroxy-2-dipropylaminotetralin (+)8-OH-DPAT) was 
purchased from Tocris (Ellisville, MO). (+)8-OH-DPAT was dissolved in 0.85% NaCl (saline) at 
a concentration of 0.2mg/ml and administered at a dose of 0.2mg/kg, s.c. Solutions were made 
fresh before injection. 
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Procedures 
Experiment 1: effect of estradiol on 5-HT1A receptor function 
Prior to surgery, rats were anesthetized by an intraperitoneal (i.p.) injection of a cocktail of 
ketamine hydrochloride (100mg/kg) plus xylazine hydrochloride (7mg/kg). Rats were 
ovariectomized (OVX) by removing both ovaries via a single ventral midline incision. Five days 
after OVX, rats were given s.c. injections of either EB (10µg/kg, 0.25ml/kg, s.c.) or vehicle 
(sesame oil) once a day for two days. 18h following the last injection of EB or vehicle, rats were 
injected with the selective 5-HT1A receptor agonist, (+)8-OH-DPAT (0.2mg/kg, s.c.) or vehicle 
(saline). 15 minutes later, animals were sacrificed by decapitation. Trunk blood was collected in 
centrifuge tubes containing 0.5ml 0.3M EDTA (pH 7.4). Brains were removed and snap-frozen 
in isopentane and dry ice. Plasma and brains were stored at -80°C until use. 
 
Experiment 2: effect of recombinant adenovirus containing GPR30 siRNA on EB-induced 
desensitization of 5-HT1A receptors 
Generation and evaluation of recombinant adenoviruses  
Recombinant adenoviruses were generated as described previously
213,240
. Briefly, potential 
GPR30 siRNA sequences were designed using Block It™RNAi Designer program provided by 
Invitrogen. Four potential siRNAs and two mismatch sequences (Table 1) were converted to 
DNA sequences to further test and generate recombinant adenovirus. The potential GPR30 
siRNAs were evaluated using a pSOS-HUS vector, which contains an siRNA site and a target 
gene site that allows transfection of siRNAs and the target gene into the same cells. A sequence 
encoding green fluorescent protein (GFP) is adjacent to an internal ribosome entry site (IRES), 
followed by the target gene cloning site, so that observed GFP expression can be used as a 
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marker for GPR30 expression. When an siRNA inhibits the transcription of GPR30, the 
expression of GFP is also reduced. Therefore, the expression of GFP observed can be used as a 
marker for GPR30 expression.  
 A full sequence of GPR30 (Accession No: U92802) (SOS-GPR30-HUS) was cloned 
into the target gene cloning site. The siRNA or mismatch siRNA sequences were inserted into 
sfiI sites of SOS-GPR30-HUS (SOS-GPR30-siRNA-HUSs and SOS-GPR30-mis-HUSs, 
respectively) as described by Luo et al
240
, followed by NotI digestion after ligation. The clones 
containing siRNA sequences were identified by PCR with U6 forward and siRNA antisense 
primers. The SOS-GPR30-siRNA-HUSs or SOS-GPR30-mis-HUSs were transfected into 
HEK293 cells using lipofectamine reagent (Invitrogen, Carlsbad, CA) to evaluate the 
knockdown efficiency of the GPR30 siRNAs. The number and density of GFP-expressing cells 
were observed for five consecutive days after the transfection.   
 The sequences of siRNAs in the SOS-GPR30-siRNA-HUS that significantly reduced the 
number and brightness of GFP-containing cells as well as SOS-GPR30-mis-HUSs that had no 
effect on GFP were selected and inserted into pSES-HUS vector. pSES-HUS is a shuttle vector 
for adenovirus and contains a red fluorescent protein (RFP), as described above and Luo et al
240
. 
The SES-GPR30-siRNA-HUSs and SES-GPR30-mis-HUSs were further recombined into Ad-
Easy-1 vector to generate high titer adenoviruses containing the GPR30 siRNA or mismatch 
sequences (GPR30-siRNA-Ads and GPR30-mis-Ads, respectively)
241
. The high titer GPR30-
siRNA-Ads and GPR30-mis-Ads (~10
11-12
 active viral particles/ml) were stored at -80°C. Before 
use, the high titer adenoviruses were dialyzed with saline for at least 40min at 4°C followed by 
1:1 dilution with saline to reduce tissue damage caused by the high-salt storage solution. 
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 To test the GPR30-siRNA-Ads in vivo, we conducted two studies. First, we tested the 
time-course of GPR30 knockdown by GPR30-siRNA-Ads. Then, we confirmed that knockdown 
of GPR30 was due to the GPR30-siRNA-Ads and not due to the viral injection or infection. Rats 
were anesthetized and OVX as described in experiment 1, then given unilateral intra-PVN 
injections of GPR30-siRNA-Ads (402, 737, and 1135 combined) using stereotaxic technique at a 
rate of 0.5µl/min, 1 or 2µl/side at the coordinates of AP= -1.8, ML= 0.5 and DV= -8.3 mm with 
respect to the bregma. The needle (31 gage) was left in the injection site for an additional 20min 
to reduce movement of the viral solution into the needle track. Three, five, or 10 days after 
injection, rats were sacrificed and the brains were removed. Brains were sectioned into 300µm 
sections using a cryostat. Regions with viral injection as indicated by RFP and the contralateral 
regions (as controls) were punched out for immunoblot analysis of GPR30. The percent 
inhibition of GPR30-siRNA-Ads was calculated by comparing the ratio of GPR30:β-actin 
between the injected side (I) and the contralateral side (C) of each animal (% inhibition = (1-I/C) 
x 100%).  
 To confirm that the observed knockdown of GPR30 protein was due to the GPR30-
siRNA-Ads and not a result of the virus itself or tissue damage caused by the injection, OVX rats 
were given unilateral intra-PVN injections of saline, control-Ad (Adtrack, empty recombinant 
shuttle vector), GPR30-mis-Ads (737 and 1135 combined), or GPR30-siRNA-Ads (402, 737, 
and 1135 combined) using stereotaxic technique as described above. Five days after injection, 
rats were sacrificed and the brains were collected to evaluate the efficiency of knockdown of 
GPR30 expression by the siRNAs, compared to the various controls, as described above. 
 
Table 3.1: Primers for generation of siRNA and mismatch siRNA constructs. S = sense; AS = 
antisense. Numbers refer to starting base pair. 
 43 
 
siRNA  
GPR30-737-S AGCCTGTGCTATTCCCTCATTTTT 
GPR30-737-AS AATGAGGGAATAGCACAGGCTTTT 
GPR30-1135-S AACGGAGCAGTCAGATGTCAAGTTCATTTT 
GPR30-1135-AS ATGAACTTGACATCTGACTGCTCCGTTTTT 
GPR30-402-S AGGACGAGCAGTATTACGATTTTT  
GPR30-402-AS AATCGTAATACTGCTCGTCCTTTT 
GPR30-272-S AGCAACATCCTCATCTTGGTGGTGAATTTT 
GPR30-272-AS ATTCACCACCAAGATGAGGATGTTGCTTTT 
Mismatch  
GPR30-1135mis-S AACGGACGGACTTGTAGAACTAGTCATTTT 
GPR30-1135mis-AS ATGACTAGTTCTACAAGTCCGTCCGTTTTT 
GPR30-402mis-S AGGAACGATATGCATGCGATTTTT  
GPR30-402mis-AS AATCGCATGCATATCGTTCCTTTT 
 
 
 
Effect of GPR30-siRNA-Ad on EB-induced desensitization of 5-HT1A receptors in the PVN 
Rats were anesthetized and OVX as described above, then given bilateral intra-PVN injections of 
control-Ad or GPR30-siRNA-Ads (402, 737, 1135 combined) using stereotaxic technique at a 
rate of 0.5µl/min, 1µl/side at the coordinates of AP= -1.8, ML= ±0.5, and DV= -8.3 mm with 
respect to bregma. The needle was left in the injection site for an additional 20min to reduce 
movement of the viral solution into the needle track. Five days after OVX and viral injection, 
rats were treated with either 10µg/kg/day EB or oil (s.c.) once a day for two days. 18h after the 
last EB or oil treatment, rats were injected with 0.2mg/kg (+)8-OH-DPAT or saline (s.c.) and 
sacrificed via decapitation 15 minutes later. Brains were removed and snap-frozen in dry-ice-
cooled isopentane and then on dry ice. Trunk blood was collected in tubes containing 0.5ml 3M 
EDTA (pH 7.4). Brains and plasma were stored at -80°C until use. 
 
Radioimmunoassay of plasma OT and ACTH 
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Plasma OT was determined by a radioimmunoassay as previously described with minor 
modifications
190
. Briefly, OT was extracted from 0.5 ml plasma with 1ml cold acetone followed 
by 2.5ml petroleum ether. The ether layer was aspirated and the samples were dried in a 
Centrivap vacuum concentrator at 4°C. The dried OT residue was resuspended in 1ml of cold 
assay buffer (0.05M phosphate buffer pH 7.4 containing 0.125% bovine serum albumin and 
0.001M EDTA). The plasma extracts were used for the radioimmunoassay as previously 
described. The radioactive 
125
I oxytocin (specific activity: 2200 Ci/mmol) was obtained from 
Perkin Elmer (Waltham, MA). Several standard recovery samples containing 0.5ml pooled 
plasma and 8 and 16 pg OT were included throughout the extraction and assay procedure. The 
plasma OT concentrations were calculated based on the recovery and dilution factors. Plasma 
ACTH concentrations were determined by radioimmunoassay as previously described
242
. 
125
I 
ACTH (0.00102mCi) was obtained from DiaSorin (Stillwater, MN). 
 
Quantitative Real-Time PCR 
RNA was isolated from the PVN using TRI-Reagent according to the manufacturer’s instruction 
(Sigma-Aldrich, St. Louis, MO). Briefly, 5µg RNA was treated with 5µl DNase I in DNase I 
buffer (total reaction volume 15µl) for 15min at room temperature; the reaction was stopped with 
5µl 25mM EDTA followed by incubation at 65°C for 10min. 10µl of the DNase-treated RNA 
reaction mixture was incubated with 1µl 0.3M oligo(dT)20 and 1µl 10mM dNTPs at 65°C for 5 
minutes. A master mix containing 5x reverse transcriptase buffer, 0.1M DTT, RNase Out, and 
200 units Superscript II enzyme (Invitrogen, Carlsbad, CA) was added to each sample according 
to the manufacturer’s protocol. The reverse transcription was performed by incubation at 42°C 
for 50min and then 70°C for 15min. 1µl RNase H was then added to the reaction which was then 
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incubated at 37°C for 20 min. The complimentary DNA (cDNA) generated was used for real-
time PCR. 
 Real-time quantitative PCR (qPCR) was performed in 96-well plates using SYBR Green 
Plus master mix (Invitrogen, Carlsbad, CA) and the Applied Biosystems 7500 Fast Real-Time 
PCR system (Applied Biosystems, Carlsbad, CA). mRNA levels of GPR30, 5-HT1A receptor, 
and RGSz1 were examined using the primers listed in Table 2. The mRNA levels were 
normalized to TATA-box binding protein (TBP) mRNA. Each qPCR reaction was conducted in 
a total volume of 20µl, containing 2µl cDNA, 10µM primers, and 10µl SYBR Green Plus master 
mix. PCR was performed at 50°C for 2min, 95°C for 10min, then 40 cycles of 95°C for 15s and 
60°C for 1min per cycle. All samples were run in triplicate. ΔCt was calculated as the target gene 
– TBP mRNA for each sample; ΔΔCt was calculated as ΔCt for the experimental condition – 
ΔCt for the control condition, for each target gene.  
 
Table 3.2: Forward and reverse primers for qPCR 
 
Gene Forward (5’---3’) Reverse (5’---3’) 
TBP  CAGGAGCCAAGAGTGAAGAACA GCTTCTGCACAACTCTAGCGTATT 
GPR30 CCACGCTCAAGGCAGTCATA GCACTGCTGAACTTGACATCTGA 
5-HT1A GATCTCGCTCACTTGGCTCAT  GCGCCAGCCCAGCAT 
RGSz1 AGACATTCCAGCGTGTGAAGAA GGGCCCAGGCACAGACTT 
 
 
Immunoblot assays 
The PVN was punched out from 300µm-thick sections prepared using a cryostat microtome. 
PVN tissue was homogenized in 100µl homogenization buffer (10mM Tris pH 7.6, 100mM 
NaCl, 1mM EDTA, 0.1% sodium cholate, 1% phosphatase inhibitor cocktail (Sigma-Aldrich, St. 
Louis, MO), 0.1% protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO)) by brief 
sonication followed by shaking for 1hr at 4°C. Samples were then centrifuged at 25,000xg for 
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1hr; the supernatant was collected and stored at -80°C. Protein concentration was measured using 
the Pierce BCA protein assay (Thermo Scientific, Rockford, IL). Protein (10µg/lane) was 
resolved on a 12% SDS-PAGE gel followed by transfer to polyvinylidene fluoride (PVDF) 
membrane. The membranes were incubated in blocking buffer (5% non-fat milk in Tris-buffered 
saline with 0.1% Tween-20 ) to reduce non-specific binding and probed overnight using the 
following primary antibodies: rabbit anti-GPR30 (1:1000, Novus Biologicals, Littleton, CO); 
rabbit anti-5-HT1A receptor (1:1000, Abcam Cat.#85615, San Francisco, CA); rabbit anti-Gαz 
(1:1000, Santa Cruz Biotechnology, Santa Cruz, CA); rabbit anti-RGSz1 (1:5000); rabbit anti-
ERβ (1:1000, Alexis Biochemicals/Enzo Life Sciences, Plymouth Meeting, PA). After washing, 
membranes were incubated with the appropriate secondary antibody conjugated with horse 
radish peroxidase. Bands were detected with ECL substrate solution (GE Healthcare 
Biosciences, Piscataway, NJ) using BioRad ChemiDoc XRS+ molecular imager (BioRad, 
Hercules, CA). Due to the limited amount of PVN protein, all primary antibodies were used on 
the same blots, with washing in between uses. Monoclonal mouse actin antibody (1:10 000, MP 
Biomedicals, Solon, OH) was used as a loading control. Bands were analyzed densitometrically 
using ImageLab software (BioRad, Hercules, CA). Each band was normalized to actin and 
calculated as percent of the control group in each blot. All samples were run in duplicate or 
triplicate. 
 
Characterization of anti-RGSz1 
RGSz1 antiserum was raised in rabbits against the last 15 amino acids of the C-terminal of 
RGSz1 (YKDLLTSLAEKTVEA) and affinity purified by Biosynthesis (Lewisville, TX). To 
characterize the antibody, the full sequence of RGSz1 was inserted into a pcDNA vector 
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(Invitrogen, Carlsbad, CA) which was then transfected into HEK293 cells. Cell lysates were 
collected, protein was separated by SDS-PAGE, and Western blotting was performed as 
described above. Representative Western blot is shown in Figure 3.2A (left). 
 
Microscopy 
18µm-Thick tissue sections were collected from the beginning, middle, and end of each 300µl  
PVN section as described above to evaluate RFP expression. Images were captured using a 
Nikon Eclipse Ti and Metamorph Software (Molecular Devices, Sunnyvale, CA) at 4x 
magnification. 
 
Statistical analysis 
All data are expressed as means ± SEM. One- or two-way analysis of variance (ANOVA) and 
Student-Newman-Keuls post hoc tests were conducted using a statistical program (Statview 
version 5.0 software, SAS Institute Inc., Cary, NC).  
 
RESULTS 
Experiment 1: Effects of EB on 5-HT1A receptor signaling in the PVN 
 EB induces desensitization of 5-HT1A receptor signaling 
In our first experiment, female SD rats were OVX and treated with EB (10µg/kg/day) for two 
days. To confirm that two-day EB treatment resulted in desensitization of 5-HT1A receptor 
signaling in our rat model, 18 hours after the second EB injection, the rats were challenged with 
the selective 5-HT1A receptor agonist (+)8-OH-DPAT (0.2mg/kg) and plasma hormone levels 
were examined. EB treatment did not alter the baseline levels of plasma OT in comparison to 
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vehicle treatment (Figure 3.1A). Activation of 5-HT1A receptors by (+)8-OH-DPAT increased 
plasma OT levels in oil-treated rats as expected. The magnitude of the OT response to (+)8-OH-
DPAT was significantly reduced in EB-treated rats (two-way ANOVA: main effect of (+)8-OH-
DPAT: F(1,25)=299.649, p<0.0001; main effect of EB: F(1,25)=11.231, p=0.0026; interaction 
between EB and (+)8-OH-DPAT: F(1,25)=12.197, p=0.0018). 
Baseline levels of plasma ACTH were unchanged by two-day EB treatment (Figure 
3.1B), and stimulation of 5-HT1A receptors by (+)8-OH-DPAT increased plasma ACTH levels 
significantly. The ACTH response to (+)8-OH-DPAT was significantly reduced in EB-treated 
animals compared to oil treatment (two-way ANOVA: main effect of (+)8-OH-DPAT: 
F(1,27)=532.827, p<0.0001; main effect of EB: (F(1,27)=9.470, p=0.0047; interaction between EB 
and (+)8-OH-DPAT: F(1,27)=11.041, p=0.0026). Thus, both oxytocin and ACTH plasma 
concentration results suggest the desensitization of 5-HT1A receptor signaling in the PVN.  
 
EB treatment alters expression of components of the 5-HT1A receptor signaling pathway  
To determine the cellular mechanisms mediating desensitization of 5-HT1A receptor signaling, 
we examined effects of EB treatment on the 5-HT1A receptor system in the PVN at the molecular 
level. EB reduced the protein levels of 5-HT1A receptors by 32% as measured on Western blots 
(Figure 3.2A, right) (F(1,5)=9.083, p=0.0296). Two RGSz1 bands (55kD, 45kD) were measured. 
The protein levels in both bands were significantly increased by 79% (F(1,5)=21.753, p=0.0035) 
and 25% (F(1,5)=6.75, p=0.0484), respectively, in the EB group compared to the oil-treated group. 
There were no significant differences in the protein levels of either Gαz protein (F(1,5)=2.256, 
p=0.2075) or GPR30 protein (F(1,5)=0.323, p=0.5943) (Figure 3.2B).  
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Quantitative real-time PCR was conducted to further examine the expression of 
components of the 5HT1A receptor signaling pathway. Our results showed that EB treatment 
increased mRNA levels of 5-HT1A receptor by 299% (EB vs. oil, F(1,6)=6.129, p=0.0481). RGSz1 
mRNA levels increased by 308% (EB vs. oil, F(1,6)=10.161, p=0.0189), while GPR30 mRNA did 
not change significantly (F(1,6)=0.000132, p=0.99) (Figure 3.2C). 
 
Experiment 2: effects of reduction in the GPR30 expression on EB-induced desensitization of 
5-HT1A receptor in the PVN 
Generation and evaluation of GPR30-siRNA-Ads 
To select efficient GPR30 siRNA sequences, SOS-GPR30-siRNA-HUSs and SOS-GPR30-mis-
HUSs were transfected into HEK293 cells. The cells transfected with GPR30-siRNA-HUS 402, 
737 and 1135, but not 272 (numbers refer to first base pairs of each siRNA sequence), displayed 
reductions in the number of GFP-containing cells and the intensity of GFP compared to SOS-
GPR30-mis-HUS and SOS-GPR30-HUS plasmids, beginning two days after transfection. 
Therefore, we selected the 402, 737, and 1135 siRNA constructs for production of GPR30 
siRNA recombinant adenovirus (GPR30-siRNA-Ad). Figure 3.3A shows examples from 3 days 
after transfection. 
To test the time course of GPR30 knockdown by GPR30-siRNA-Ads, we unilaterally 
injected 1 or 2 µl GPR30-siRNA-Ads into the PVN of rats (Figure 3.3B) and collected the 
brains 3, 5 and 10 days after the injection. By comparing GPR30 expression in the viral infected 
sides to their contralateral sides, we observed that the GPR30-siRNA-Ads significantly inhibited 
the expression of GPR30 in a dose-dependent manner (% inhibition: 59.0 ± 8.12 (n=3) for 1µl 
vs. 77.87± 4.77 (n=6) for 2µl viral injection). This inhibition of GPR30 expression was observed 
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3 days after the injections. There was no difference between 3 and 5 days, but there was a slight 
reduction in inhibition 10 days after the injection (89.47% inhibition for 3 days, 85.93% for 5 
days and 66.35% for 10 days after 2µl viral injection).  These data demonstrated that the GPR30-
siRNA-Ads are able to efficiently knock down GPR30 expression 3 days after injection. 
Although no visible tissue damage was observed, to avoid possible toxicity and to restrict the 
knockdown of GPR30 to the PVN, we used 1µl of GPR30-siRNA-Ads and the 5 day time point 
in further studies.  
To compare the effects of the GPR30-siRNA-Ads with the GPR30-mis-Ads in vivo, we 
unilaterally injected 1µl of GPR30-siRNA-Ads into the PVN, with saline, empty viral vector 
(Adtrack, control-Ad), or GPR30-mis-Ads as controls. In the GPR30-siRNA-Ads construct, red 
fluorescent protein (RFP) is expressed independently of the siRNAs, making the presence of 
RFP useful for tracking the virus infection (Figure 3.3C). Five days after the injection of the 
virus, GPR30 protein level in the viral-infected side was measured and percent inhibition was 
calculated relative to the contralateral (non-injected) side of each animal (representative Western 
blots shown in Figure 3.3D). The GPR30-siRNA-Ads were successful in reducing GPR30 
protein expression by about 42%, compared to the contralateral side (F(3,10)=6.225, p=0.0118). 
None of the three controls had a significant effect on GPR30 protein levels (Figure 3.3E). 
However, in a separate experiment (not shown), GPR30-mis-Ads interfered with the 
neuroendocrine response. Therefore, we used control-Ad as the control for the following 
experiment.  
 
Effect of GPR30-siRNA-Ads on GPR30 in the PVN 
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To determine the role of GPR30 in the EB-induced desensitization of 5-HT1A receptor signaling 
in the PVN, we performed bilateral injections of control-Ad or GPR30-siRNA-Ad constructs in 
the PVN of OVX rats. Five days after viral injection, rats were treated with 10µg/kg/day EB or 
oil (s.c.) for two days and then challenged with 0.2mg/kg (+)8-OH-DPAT (s.c.) before being 
sacrificed, as described above. Knockdown of GPR30 was verified by Western blotting (Figure 
3.4A). We used both reduction in GPR30 levels and the location of RFP expression as exclusion 
criteria for incorrect injections of GPR30-siRNA-Ads; rats with no RFP or RFP that was not in 
the PVN were excluded from subsequent analyses. GPR30 protein was successfully reduced to 
about 68% of control (F(1,12)=7.856, p=0.0160) (Figure 3.4B). This 32% inhibition is a little 
lower than the reduction in the previous test. This could be due to the way tissue was collected 
and GPR30 levels compared: we measured GPR30 in the entire PVN if there was viral infection 
in at least part of the PVN, whereas previously we only injected one side of the PVN and only 
used tissue that had RFP expression. ERβ expression can be influenced by treatment with 
estradiol 
213
; to ensure that effects of EB on 5-HT1A receptor signaling in the neuroendocrine 
challenge tests were due to the reduction of GPR30 and not a change in ERβ levels, we measured 
ERβ protein in the PVN following infection with GPR30-siRNA-Ads and found no significant 
change (F(1,15)=1.913, p=0.1773) (Figure 3.4). 
 
Effect of GPR30-siRNA-Ads on EB-induced desensitization of 5-HT1A receptor signaling 
Desensitization of 5-HT1A receptor signaling was examined by measuring the plasma levels of 
OT (Figure 3.5A) and ACTH (Figure 3.5B). The baseline level of plasma OT was not altered by 
EB treatment or GPR30-siRNA-injection. In animals injected with the control-Ad, activation of 
5-HT1A receptors by (+)8-OH-DPAT increased plasma OT levels. In the control-Ad-infected 
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group, there was a significant reduction in OT response to (+)8-OH-DPAT after EB treatment 
compared to oil treatment, demonstrating desensitization of 5-HT1A receptor signaling. In the 
GPR30-siRNA-Ads-injected group, OT levels in response to (+)8-OH-DPAT were not 
significantly different from the control-Ad-injected, oil-treated group, and EB treatment did not 
induce 5-HT1A receptor signaling desensitization (three-way ANOVA: main effect of viral 
injection, F(1,56)=2.193, p=0.1442; main effect of (+)8-OH-DPAT, F(1,56)=1219.852, p<0.0001; 
main effect of EB ,F(1,56)=4.208, p=0.0449; interaction between EB and (+)8-OH-DPAT, 
F(1,56)=2.162, p=0.1471; interaction between EB and viral injection, F(1,56)=0.719, p=0.4002; 
interaction between (+)8-OH-DPAT and viral injection, F(1,56)=2.393, p=0.1275; interaction 
between EB, (+)8-OH-DPAT, F(1,56)=0.3866, p=0.761). 
Plasma ACTH levels in response to (+)8-OH-DPAT showed a similar pattern. Neither 
EB treatment nor GPR30-siRNA-Ad injection had an effect on baseline levels of plasma ACTH.  
In animals injected with the control-Ad, activation of 5-HT1A receptors by (+)8-OH-DPAT 
increased plasma ACTH levels, while EB treatment produced a significant reduction in ACTH 
response to (+)8-OH-DPAT, demonstrating desensitization of 5-HT1A receptor signaling. In the 
GPR30-siRNA-Ad-injected group, ACTH levels in response to (+)8-OH-DPAT were not 
significantly different from the control-Ad-injected, oil-treated group, and EB treatment did not 
have an effect on plasma ACTH levels (three-way ANOVA: main effect of viral injection, 
F(1,62)=1.939, p=0.1688; main effect of (+)8-OH-DPAT, F(1,62)=802.128, p<0.0001; main effect 
of EB, F(1,62)=0.688, p=0.4100; interaction between (+)8-OH-DPAT and EB, F(1,62)=1.930, 
p=0.1697; interaction between (+)8-OH-DPAT and viral injection, F(1,62)=0.3849, p=0.766; 
interaction between EB and viral injection, F(1,62)=5.122, p=0.271; interaction between (+)8-OH-
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DPAT, EB, and viral injection, F(1,62)=5.043, p=0.0283). Together, these results suggest that 
GPR30 is necessary for desensitization of 5-HT1A receptor signaling. 
To further investigate the effects of EB treatment on 5-HT1A receptor signaling, we next 
examined 5-HT1A receptor protein and the G protein mediating the hormone responses, Gαz, 
using Western blotting (Figure 3.6A). EB treatment resulted in reduced levels of 5-HT1A 
receptor protein in the control-Ad-injected group (F(1,35)=6.694, p=0.0011); this effect was not 
seen in the GPR30-siRNA-Ad-injected group, further suggesting that GPR30 may be involved in 
the reduction of 5-HT1A receptor protein. The GPR30-siRNA-Ad injection itself had no effect on 
5-HT1A receptor protein levels. Levels of Gαz protein were unchanged, regardless of treatment 
(F(1,35)=1.051, p=0.3875) (Figure 3.6B). 
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Figure 3.1. EB treatment induces 5-HT1A desensitization. Plasma OT (A) and ACTH (B) levels 
in response to saline or (+)8-OH-DPAT challenge in rats treated with oil or EB. Data are 
presented as mean ±SEM (n=6-8/group). *Significantly different from saline-challenged animals 
with same treatment, p<0.0001; #significantly different from oil/(+)8-OH-DPAT-treated 
animals, p<0.005 by Student-Newman-Keuls post hoc test. 
 55 
 
Figure 3.2. EB-induced changes in 5-HT1A signaling pathway. (A) Left, characterization of 
RGSz1 antibody. Lane 1, HEK293 cells transfected with RGSz1. Lane 2, HEK293 cells 
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transfected with empty vector (pcDNA). Lane 3, PVN tissue lysate. Right, Western blot of PVN 
protein after oil or EB treatment with antibodies against GPR30, 5-HT1A, Gαz, and RGSz1, with 
β-actin as aloading control. (B) Quantitation of protein levels after EB pretreatment, normalized 
to β-actin and expressed as percent of control (oil). Data are expressed as mean ± SEM (n=6), 
*p<0.05, **p<0.001 by Student-Newman-Keuls post hoc test. (C) qPCR of mRNA isolated from 
PVN tissue, normalized to control (oil). Changes in mRNA levels are expressed as mean 2
-ΔΔCt
 ± 
SEM (n=4-6), *p<0.05 by Student-Newman-Keuls post hoc test. 
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Figure 3.3. Generation and evaluation of recombinant adenoviruses containing GPR30-siRNAs. 
(A) Selection of GPR30-siRNAs: SOS-GPR30-siRNA-HUS (left panels), SOS-GPR30-mis-
siRNA- HUS (right panels), and SOS-GPR30-HUS (control) (right panels) constructs were 
transfected into HEK293 cells. The number and brightness of GFP-containing cells were 
observed three days after the transfection. (B) Diagram of PVN injection site. F = fornix. 
Vertical line represents the 3rd ventricle. PVN is within the dashed triangle. (C) An example of 
RFP expression in the PVN five days after unilateral injection of GPR30-siRNA-Ads. 3V = 3rd 
ventricle. (D) Examples of Western blot for GPR30 protein from PVN tissue with unilateral 
injection of saline, control-Ad, GPR30-mis-Ads, and GPR30-siRNA-Ads five days after 
infection. (E) Quantitation of GPR30 knockdown, presented as mean percent inhibition (injected 
side compared to contralateral) ± SEM (n=4-5), *p<0.05 *p<0.05 by Student-Newman-Keuls 
post hoc test. 
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Figure 3.4. Confirmation of GPR30 knockdown. (A) Examples of Western blots of GPR30 and 
ERβ with β-actin as loading control in GPR30-siRNA-Ad- and control-Ad-injected PVN. (B) 
Quantitation of GPR30 knockdown and ERβ protein levels in the PVN of GPR30-siRNA-Ad- 
and control-Ad-injected rats. Data are expressed as mean percent of control-Ad ± SEM (n=4-7), 
*p<0.01 by Student-Newman-Keuls post hoc test. 
 59 
 
Figure 3.5. Effects of GPR30-siRNA-Ads on plasma OT (A) and ACTH (B) responses to (+)8-
OH-DPAT in EB-treated rats. Data are expressed as mean ± SEM, (n=7-10). *Indicates 
significantly different from saline-challenged animals with same treatment, p<0.0001, #indicates 
significantly different from control-Ad/oil-treated rats with same challenge, p<0.05 by Student-
Newman-Keuls post hoc test. 
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Figure 3.6. GPR30-siRNA-Ads prevented EB-induced reductions of 5-HT1A receptor protein in 
the PVN. (A) Representative Western blots of 5-HT1A receptor and Gαz protein levels with β-
actin loading control in the PVN of rats injected with control-Ad or GPR30-siRNA-Ad followed 
by treatment with oil or EB. (B) Quantitation of Western blots. Data are expressed as mean 
percent of control-Ad/oil, ± SEM (n=7-12) after normalization to β-actin. *p<0.001 by Student-
Newman-Keuls post hoc test. 
 
DISCUSSION 
We previously reported that 2-day peripheral administration of EB resulted in the 
desensitization of 5-HT1A receptor signaling in the rat PVN
204,243
. Our previous study 
demonstrated that this desensitization is not mediated by ERβ, as treatment with a selective ERβ 
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agonist, DPN, did not mimic the results of EB treatment. Furthermore, siRNA knockdown of 
ERβ in the PVN did not prevent EB-induced desensitization of 5-HT1A receptor signaling
213
. 
However, 2-day intra-PVN injections of the selective GPR30 agonist, G-1, did result in 
desensitization of 5-HT1A receptor signaling
143
. Therefore, in this study we chose to focus on the 
role of GPR30. We show for the first time that GPR30 expression is necessary for the EB-
induced desensitization of 5-HT1A receptor signaling, and that this mechanism involves a 
decrease in 5-HT1A receptor protein expression and possibly an increase in the rate of Gαz-GTP 
hydrolysis, as suggested by an increase in RGSz1 protein expression. 
To identify the role of GPR30 in EB-induced changes in 5-HT1A receptor signaling, we 
injected an adenovirus containing siRNA sequences against GPR30 directly into the PVN. 
Treatment with GPR30-siRNA-Ads produced a modest reduction of GPR30 protein, by about 
32%. Despite such a modest reduction in GPR30 protein, GPR30-siRNA-Ads infection was 
successful in completely preventing the reduction of both the OT and ACTH hormone responses 
to (+)8-OH-DPAT produced by EB treatment, reinforcing the hypothesis that GPR30 is 
necessary for estradiol-induced 5-HT1A receptor desensitization.  
 To further elucidate the GPR30-mediated mechanism through which EB impacts 5-HT1A 
receptor desensitization, we examined changes in the 5-HT1A receptor signaling pathway. Two-
day treatment with EB resulted in a decrease in 5-HT1A receptor protein in the PVN, which is 
consistent with previous studies that have reported a decrease in 5-HT1A receptor binding sites in 
the hypothalamus and DRN of nonhuman primates
169
 and reduced 5-HT1A receptor protein levels 
in the DRN 
244
 after chronic estradiol treatment. In contrast, we found that 2-day EB treatment 
increased 5-HT1A receptor mRNA. This upregulation of 5-HT1A receptor mRNA in the PVN may 
be a feedback response to the decrease in protein levels induced by estradiol, or estradiol 
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signaling may be affecting 5-HT1A receptor translational control. Other studies have 
demonstrated that acute estradiol administration decreased 5-HT1A receptor gene expression in 
the rat limbic system 
245
, while chronic estradiol decreased 5-HT1A receptor mRNA in the rat 
DRN
246
 but increased 5-HT1A receptor mRNA in the DRN in nonhuman primates 
247
. These 
discrepancies could be due to tissue-specific regulatory mechanisms, differences in chronic 
versus short-term estradiol administration, or species differences. Notably, the 32% reduction in 
GPR30 induced by infection with the GPR30-siRNA-Ads prevented the EB-induced changes in 
5-HT1A receptor protein, thus reinforcing an important role for GPR30 in this mechanism.  
 There are some studies linking changes in 5-HT1A receptor expression to depression in 
human female patients
248
, which would indicate a role for estradiol in mediating 5-HT1A receptor 
expression as well as function. Pet-1, which is necessary for development of the serotonin 
system
249-252
, directly binds to Pet-1 elements in the human 5-HT1A receptor promoter region, 
and is critical for 5-HT1A receptor expression in the midbrain
253
. In macaques, long-term OVX 
reduced expression of Pet-1 in the DRN
254
, while in rats, two-day administration of estradiol 
after OVX increased Pet-1 mRNA levels in the DRN
255
, indicating a clear role for regulation of 
midbrain 5-HT1A receptor expression by estradiol. A reduction in inhibitory DRN 5-HT1A 
autoreceptors, induced by estradiol via Pet-1, may play a role in desensitizing post-synaptic 5-
HT1A receptors in the PVN by increasing serotonergic tone, similar to chronic SSRI treatment.  
Though GPR30 is a membrane receptor that signals through heterotrimeric G proteins, 
studies have demonstrated that signaling through GPR30 has effects on gene transcription, 
independent of classical estrogen response elements
136,148
. GPR30 has been shown to act 
independently of ERα and ERβ to stimulate the MAPK/ERK1/2 signaling system via a PTX, 
Gβγ pathway
132,256
. We showed previously that treatment with PTX inhibits modulation of 5-
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HT1A receptor signaling by estradiol
143
, which again suggests that GPR30 signaling plays a role 
in this mechanism. In the current study, we saw an estradiol-induced decrease in 5-HT1A receptor 
expression that was precluded by GPR30 protein reduction. This suggests that estradiol could 
alter 5-HT1A receptor expression levels through the GPR30-Gβγ, MAPK/ERK1/2 pathway to 
transiently decrease 5-HT1A receptor mRNA in the PVN. The subsequent decrease in 5-HT1A 
receptor protein levels could then feedback to lead to upregulation of mRNA expression, though 
the mechanisms remain unclear 
5-HT1A receptors in the PVN are coupled to the G protein Gαz to stimulate OT and 
ACTH (via CRF) release
49,215,216
. Previous studies have shown that chronic estradiol treatment 
results in decreased DRN protein levels of Gαi3, but not Gαi1, Gαi/o, or Gαz in nonhuman 
primates 
169
. Similarly, in the present study we found that 2-day EB administration had no effect 
on Gαz protein or mRNA levels in the PVN. These results are consistent with previous reports 
showing that EB treatment does not affect levels of Gαz protein in the rat PVN
219,243
. 
Knockdown of GPR30 by GPR30-siRNA-Ads also had no effect on Gαz levels, indicating that 
GPR30 signaling does not regulate Gαz protein levels, and that alterations of Gαz levels are not 
responsible for estradiol-mediated 5-HT1A receptor desensitization. 
While a decrease in 5-HT1A receptor protein expression may play a role in EB-induced 
desensitization, it is interesting that estradiol treatment also reduces 5-HT1A receptor 
function
204,243,257,258
 and coupling to G proteins
259
, though we show that Gαz protein expression 
is not affected by EB. We therefore examined protein and mRNA expression of RGSz1, the GAP 
that is highly selective for Gαz
79,80,217
. Consistent with a previous report
219
, we found that 2-day 
EB treatment increased RGSz1 protein and now have found an increase in RGSz1 mRNA in the 
PVN. By increasing the hydrolysis of Gαz-GTP by over 400-fold
80
, high levels of RGSz1 could 
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effectively reduce the ability of Gαz to activate downstream effectors and hormone release upon 
5-HT1A receptor stimulation, thus contributing to the desensitized response. Work is currently 
being done in our laboratory to investigate the potential interactions between RGSz1, Gαz, and 
5-HT1A receptors. 
Since OT-containing neurons express very little ERα
239
, we have not yet directly 
addressed ERα as a potential candidate for desensitization of 5-HT1A receptor signaling. 
However, some studies have shown that hypothalamic neurons, as well as other cell types, have a 
number of ERα splice variants that are located in the plasma membrane and could mediate 
estradiol signaling
126,260-265
. Recent studies have found a novel, membrane-targeted, 36kD splice 
variant (ERα36) with a unique C-terminal sequence in human tissues and human cell lines
266,267
, 
and suggest that ERα36 may be involved in responses heretofore believed to be mediated by 
GPR30. In ER-negative breast cancer cell lines that express ERα36 (e.g. MDA-MB-231 and SK-
BR-3), the selective estrogen receptor modulator tamoxifen and ER antagonist ICI 182, 780 were 
unable to block nongenomic estrogen signaling
268,269
, similar to effects seen when GPR30 is 
expressed
137
. A recent study by Kang et al. 
270
 demonstrated that GPR30 expression and 
signaling induced ERα36 expression, that G-1 specifically binds and activates ERα36, and that 
ERα36 mediates nongenomic estrogen signaling independent of GPR30 in full-length-ERα-
negative but ERα36-positive breast cancer cells. They suggest that GPR30 signals through the 
Src/MAPK/AP-1 pathway to activate ERα36 promoter activity and induce ERα36 expression, 
and that G-1 may be an agonist for ERα36, not GPR30. Other studies have reported ERα36 
effects or immunoreactivity in rodent tissues; however, they failed to directly demonstrate 
expression of this splice variant
271,272
. Indeed, we performed immunohistochemical staining of 
rat brain tissue using the antibody kindly provided by Wang’s group
269
, raised against the unique 
 65 
C-terminal sequence of ERα36, and found strong immunoreactivity in neurons throughout the rat 
brain. However, we conducted a BLAST search for the unique 88 base pair sequence of human 
ERα36 in the rat genome and no comparable sequence was detected. These data suggest that 
while it is possible that the rat brain may contain an ERα splice variant that plays a role in 
estradiol-GPR30 signaling, this putative splice variant is not the same as the ERα36 described in 
humans.  
 The results of this study demonstrate that GPR30 expression is necessary for estradiol-
induced desensitization of 5-HT1A receptor signaling in the PVN, and that the mechanism likely 
involves a decrease in 5-HT1A receptor protein levels and an increase in RGSz1 expression. 
Further studies are needed to clarify whether ERα or any of its splice variants play a role in this 
mechanism. Because the effects of SSRIs occur slowly and are thought to involve desensitization 
of pre-synaptic and post-synaptic 5-HT1A receptors
21,101,201,234,235
, elucidating the estrogen-
receptor-mediated mechanisms that result in rapid desensitization of 5-HT1A signaling will be 
important in the design of novel treatments that activate specific estrogen receptors in 
conjunction with SSRI therapy, for the improved treatment of depression and other mood 
disorders. 
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CHAPTER FOUR 
 
GPR30 STIMULATION ALTERS POSTTRANSLATIONAL MODIFICATION OF RGSZ1 
AND INDUCES DESENSITIZATION OF 5-HT1A RECEPTOR SIGNALING IN THE RAT 
HYPOTHALAMUS 
 
ABSTRACT 
Desensitization of 5-HT1A receptor (5-HT1AR) signaling in the PVN is associated with effective 
SSRI antidepressant treatment, which in rats takes seven days to develop. Estradiol alone 
produces a partial desensitization of 5-HT1AR signaling, and synergizes with SSRIs to result in a 
rapid and complete desensitization with two days of treatment as measured by a decrease in the 
oxytocin and ACTH responses to selective stimulation of 5-HT1AR. GPR30 is necessary for 
estradiol-induced desensitization of 5-HT1AR signaling, although the mechanisms underlying this 
effect are still unclear. The purpose of this study was to determine whether peripheral delivery of 
the GPR30 selective agonist G-1 could induce desensitization of 5-HT1AR signaling, and to 
investigate the effects of treatment on 5-HT1AR signaling components. Two-day systemic G-1 
treatment produced partial desensitization of oxytocin and ACTH responses to 5-HT1AR 
stimulation. Estradiol and G-1 treatment produced dramatic alterations to a GTPase activating 
protein selective for Gαz, RGSz1, which likely represent changes in posttranslational 
modification. RGSz1 isoforms are differentially glycosylated, sumoylated, and phosphorylated, 
and are differentially distributed in subcellular organelles. Sumoylated and glycosylated RGSz1 
localized to the detergent resistant microdomain (DRM) of the plasma membrane, and was 
increased by estradiol and G-1 treatment. Because active Gαz also localizes to the DRM, 
increased DRM-localized RGSz1 could functionally reduce Gαz downstream signaling, and thus 
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reduce oxytocin and ACTH release. Together, these results identify GPR30 and RGSz1 as 
targets for the development of new adjuvants for the treatment of depression. 
 
INTRODUCTION 
Mood disorders are more prevalent in women
192,273,274
 and depression is associated with 
periods of hormone fluctuation and reduction in estrogen levels
226,227,275-277
, suggesting a gender-
dependent risk factor for the development of mood disorders. In rodents, females exhibit higher 
sensitivity to serotonergic stimulation and increased hypothalamic-pituitary-adrenal (HPA) axis 
activity compared to males
103
. Serotonin is a major mediator of the HPA axis, and change in 
serotonergic function is a hallmark of many neuropsychiatric disorders. Dysregulation of the 
HPA stress axis is the most common and predictive physiological symptom in 
depression
87,278,279
, and normalization of the stress response is associated with successful 
antidepressant treatment
84
.  
Recent studies have shown that depression-like behavior in rodents is modulated by 
specific serotonin receptors, in particular 5-HT1AR
280,281
. Chronic treatment with SSRIs produces 
desensitization (attenuation) of 5-HT1AR signaling in the PVN, as measured by a reduction in the 
OT and ACTH response to 5-HT1AR stimulation
187,282,283
. It takes 3-12 weeks to achieve clinical 
efficacy with SSRIs; this therapeutic lag is thought to be partly due to the time it takes for 
desensitization of 5-HT1AR signaling in the PVN to occur
201-203
.  
Neuroendocrine challenge tests that detect peripheral changes in hormone responses to 5-
HT1AR agonists can be used to measure desensitization of 5-HT1AR signaling in the PVN
190,236
. 
Recently, we have shown that 2-day estradiol treatment accelerates SSRI-induced 5-HT1AR 
desensitization
206
, which may have clinical relevance to decrease therapeutic lag. However, 
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because estrogen therapy in peri- and post-menopausal women is associated with increased risk 
of breast cancer, stroke, and heart disease
207,209,284
, identifying the estrogen receptor and 
associated changes in 5-HT1AR signaling components that contribute to desensitization will 
suggest new targets for the treatment of depression. 
 Previous data in our laboratory have demonstrated that estradiol signaling through the 
membrane estrogen receptor GPR30 is both necessary and sufficient for estradiol-induced 
desensitization of 5-HT1AR signaling
143,220
, but the effect of GPR30 signaling on 5-HT1AR 
signaling components to produce desensitization is still unclear. In the PVN, 5-HT1AR couples to 
Gαz to mediate the release of OT and ACTH
49
. Gαz is active in the GTP-bound form and has a 
very slow intrinsic rate of GTP hydrolysis. RGSz1, a regulator of G protein signaling, has a high 
affinity for Gαz and increases the rate of GTP hydrolysis by over 400-fold, effectively down-
regulating Gαz downstream signaling
79,80,217
. Increased RGSz1 activity could therefore 
contribute to desensitization of 5-HT1AR signaling. 
RGSz1 is part of the RGS-Rz subfamily of RGS proteins
67
 and is an alternative splice 
variant of the RGS20 gene, which is expressed almost exclusively in nervous tissue
79
. RGSz1 in 
the rat is a 242 amino acid protein containing the RGS-Rz conserved domain (RGS box) that 
binds the GαGTP subunit to accelerate hydrolysis. The predicted molecular weight of RGSz1, 
based on its amino acid sequence, is 27-29kD. However, RGSz1 in the brain displays protein 
isoforms of many different sizes, which may represent different posttranslational modifications. 
We have shown previously that 2-day estradiol treatment resulted in an increase in RGSz1 
mRNA, as well as RGSz1 proteins
219,220
. RGSz1 has been shown to undergo posttranslational 
modification in isolated mouse synaptosomal membranes, including glycosylation, 
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SUMOylation, and phosphorylation
73,218
, which may affect its interaction with and ability to 
regulate Gαz and thus contribute to desensitization of 5-HT1AR signaling.  
In this study, we investigated the hypothesis that alterations in RGSz1 expression and 
posttranslational modification after GPR30 stimulation underlie estradiol-induced desensitization 
of 5-HT1AR signaling. To test this hypothesis, we pretreated ovariectomized rats with estradiol or 
the GPR30 selective agonist G-1 to induce desensitization of 5-HT1AR signaling, and found that 
G-1 and estradiol pretreatment significantly altered specific RGSz1 isoforms. To further 
investigate how these changes could underlie desensitization of 5-HT1AR signaling, we examined 
and characterized these isoforms, including identifying the different posttranslational 
modifications and subcellular localization of the different RGSz1 isoforms. 
 
MATERIALS AND METHODS 
Animals 
Female OVX Sprague-Dawley rats (225-250g) purchased from Harlan (Haslett, MI) were housed 
two per cage in a temperature-, humidity-, and light-controlled room (12 h light/dark cycle). 
Food and water were available ad libitum. All procedures were conducted in accordance with the 
National Institutes of Health Guide for the Care and Use of Laboratory Animals and as approved 
by the University of Kansas Institutional Animal Care and Use Committee. All efforts were 
made to minimize animal discomfort and to reduce the number of animals used. 
 
Drugs  
17β-Estradiol-3-benzoate (EB) was purchased from Sigma-Aldrich (St. Louis, MO). EB was first 
dissolved in 100% ethanol to a concentration of 25µg/ml and then diluted to the final 
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concentration with sesame oil. The EB solution and sesame oil were administered at 0.4ml/kg 
(EB dose 10µg/kg subcutaneous (s.c.)). G-1 (1-(4-(6-Bromobenzo[1,3]dioxol-5-yl)-3a,4,5,9b-
tetrahydro-3H-cyclopenta[c]quinolin-8-yl)-ethanone)) was purchased from EMD Chemicals 
(Newark, NJ). G-1 was dissolved in 100% DMSO to a concentration of 5mg/ml and 10mg/ml 
and administered at 0.5ml/kg (G-1 dose 2.5mg/kg and 5mg/kg s.c.). Fluoxetine-HCl (Sigma-
Aldrich, St. Louis, MO) was dissolved in 0.85% NaCl (saline) at a concentration of 5mg/ml and 
administered at 2ml/kg (fluoxetine dose 10mg/kg s.c.). (+)8-Hydroxy-2-dipropylaminotetralin 
((+)8-OH-DPAT) was purchased from Tocris (Ellisville, MO). (+)8-OH-DPAT was dissolved in 
0.85% NaCl (saline) at a concentration of 0.2mg/ml and administered at a dose of 0.2mg/kg s.c. 
Solutions were made fresh before injection. 
 
Experimental Procedure 
Effects of G-1 treatment on desensitization 5-HT1AR signaling in the PVN 
5 days after OVX, rats were treated with either EB (10µg/kg/day), 2.5 or 5 mg/kg/day G-1, or 
vehicle (DMSO) once a day for 2 days. 18h after the last G-1 or vehicle treatment, rats were 
injected with 0.2mg/kg (+)8-OH-DPAT or saline and sacrificed via decapitation 15 minutes later. 
Brains were removed and snap-frozen in dry-ice-cooled isopentane and then on dry ice. Trunk 
blood was collected in tubes containing 0.5ml 3M EDTA (pH 7.4). Brains and plasma were 
stored at -80°C until use. 
Effects of G-1 and fluoxetine combined on desensitization 5-HT1AR signaling in the PVN 
5 days after OVX, rats were treated with either EB (10µg/kg/day), 5 mg/kg/day G-1, fluoxetine 
(10 mg/kg/day), EB/fluoxetine combined, G-1/fluoxetine combined, or vehicle (DMSO) once a 
day for 2 days. 18h after the last treatment, rats were injected with 0.2mg/kg (+)8-OH-DPAT or 
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saline and sacrificed via decapitation 15 minutes later. Brains were removed and snap-frozen in 
dry-ice-cooled isopentane and then on dry ice. Trunk blood was collected in tubes containing 
0.5ml 3M EDTA (pH 7.4). Brains and plasma were stored at -80°C until use. 
 
Biochemical assays 
Radioimmunoassay of plasma oxytocin and ACTH  
Plasma oxytocin and ACTH were determined by radioimmunoassay as previously described with 
minor modifications
190,242
. The radioactive 125I oxytocin and 125I ACTH (specific activity of 
each: 2200 Ci/mmol) were obtained from Perkin Elmer (Waltham, MA).  
 
Subcellular fractionation of rat cortex  
Subcellular fractionation was performed as described previously
206
. Briefly, the cortex from four  
rats was homogenized in 4 volumes of homogenate buffer (0.32M sucrose, 1mM EDTA 10mM 
Tris-HCl pH 7.4, 20 mM N-ethylmaleimide (NEM), 1:100 dilution of protease inhibitor (Sigma) 
and phosphatase inhibitors II and III (Sigma)) using a Powergen 1000 homogenizer at speed 5, 
4°C for ~10 sec. After a centrifugation at 1500x g, 4°C for 15 min, the supernatant was used for 
discontinuous gradient centrifugation. Iodixanol (Optiprep, Sigma) was diluted into 7.5, 10, 12.5, 
15, 20, 25 and 30% with Diluent (0.25mM sucrose, 6mM EDTA 60mM Tris-HCl pH 7.4, 20 
mM NEM, 1:100 dilution of protease and phosphatase inhibitors). 1 ml of each solution from 
7.5% to 30% was underlaid sequentially in a 13 ml SW41 centrifuge tube. 1 ml brain 
homogenate supernatant was layered on the 5% iodixanol solution and centrifuged at 200,000x g 
at 4°C for 3 hours in a SW41 rotor. After the centrifugation, 0.5 ml fractions were collected from 
the top to the bottom of the tube. The membrane proteins were then solubilized with 50 µl 10% 
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sodium cholate, then sonicated and shaken for one hour at 4°C. The fractions were aliquoted and 
stored at -80°C until use. The protein concentration of the fractions was measured using Pierce 
BCA protein assay kit (Thermo Scientific Inc, Rockford IL). 10 µg of protein were used for 
immunoblots. All experiments were performed in triplicate. 
 
Isolation of DRM from cortex tissue 
Isolation of the detergent-resistant microdomain (DRM) was performed as described 
previously
206
. Briefly, rat cortex was homogenized with a homogenizer driven by an overhead 
motor at 500 rpm for 25 strokes in 10 volumes of homogenate buffer (10mM Tris-HCl pH 7.4, 
5mM EDTA, 320 mM sucrose, 20mM NEM, 1:100 dilution of protease and phosphatase 
inhibitor cocktails). The homogenate was centrifuged at 800xg for 15 min at 4°C to remove the 
nucleus and cell debris. The supernatant was then centrifuged at 30,000xg for 30 min at 4°C, and 
the resulting pellet was resuspended in 2.2ml of extracting buffer (50mM Tris-HCl pH 7.4, 
150mM NaCl, 5mM EDTA, 0.5% Triton X-100 (v/v), 20mM NEM, 1:100 dilution of protease 
and phosphatase inhibitor cocktails) and then incubated for 10min on ice. 2ml of the Triton X-
100-treated homogenate was adjusted to a final concentration of 40% sucrose with an 80% 
sucrose solution in extracting buffer. The 40% sucrose Triton X-100-treated homogenate was 
placed on the bottom of a 13ml centrifuge tube and overlaid with 6ml of 30% sucrose. Finally, 
2ml of 5% sucrose buffer was placed on the top of the 30% sucrose. The sucrose gradient was 
then centrifuged at 230,000xg, 4°C for 16h. After the centrifugation, 1ml fractions were 
collected from top to bottom. 0.1ml of 10% sodium cholate was added to the fractions to 
solubilized membrane proteins, which were then sonicated and shaken for 1h at 4°C. The 
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fractions were aliquoted and stored at -80°C until use. The protein concentration of the fractions 
was measured using Pierce BCA protein assay kit. 10 µg of protein were used for immunoblots. 
 
Immunoblot assays  
The PVN was punched out from 300 µm-thick sections prepared using a cryostat microtome. 
PVN tissue was homogenized in 100µl homogenization buffer (50 mM Tris, 150 mM NaCl, and 
10% sucrose, pH 7.4, 20 mM NEM, 1:100 protease and phosphatase inhibitor cocktails) using a 
Bullet Blender at speed 10, 4°C for 8 min with 1mm beads. The cortex was homogenized in 10 
volumes of homogenate buffer using a Powergen 1000 homogenizer at speed 5, 4°C for ~10 sec. 
After centrifugation at 25,000xg, 60min, at 4°C, the supernatant was reserved as the cytosol 
fraction. The membrane proteins, located in the pellet, were solubilized in 3 volumes of 
solubilization buffer (20mM Tris pH 8, 1mM EDTA, 100mM NaCl, 1% sodium cholate 
containing 20mM NEM and 1:100 protease and phosphatase inhibitor cocktails) via sonication 
followed by shaking for 1 hour at high speed, 4°C. The membrane fraction was collected after 
centrifugation at 25,000xg, 60min, at 4°C. Protein (10µg/lane) was resolved on a 12% SDS-
PAGE gel followed by transfer to polyvinylidene fluoride (PVDF) membrane. The membranes 
were incubated in blocking buffer (5% non-fat milk in Tris-buffered saline with 0.1% Tween-20) 
to reduce non-specific binding and probed overnight using the following primary antibodies: 
goat anti-SUMO2/3 1:200 (#sc-5231, Santa Cruz Biotechnology, Dallas, TX), mouse anti-
phospho(S/T/Y) 1:100 (#E3074, Spring Biosciences, Pleasanton, CA), affinity purified rabbit 
anti-RGSz1 1:100 (Biosynthesis, Lewisville, TX), mouse anti-flotillin-1 1:2000 (#610820, BD 
Biosciences, San Jose, CA), mouse anti-Na
+
/K
+
ATPase α1 1:2000 (#sc-21712, Santa Cruz 
Biotechnology), rabbit anti-calreticulin 1:2000 (#Ab4, Abcam, Cambridge, MA), goat anti-EEA1 
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(C-15) 1:1000 (#sc-6414, Santa Cruz Biotechnology), mouse anti-βactin (C4) 1:20,000 (#69100, 
MP Biomedicals, Solon, OH). After washing, membranes were incubated with the appropriate 
secondary antibody conjugated with horseradish peroxidase at a dilution of 1:10,000. Bands were 
detected with ECL substrate solution (GE Healthcare Biosciences, Piscataway, NJ) using BioRad 
ChemiDoc XRS+ molecular imager (BioRad, Hercules, CA). Bands were analyzed 
densitometrically using ImageLab software (BioRad, Hercules, CA). Each band was normalized 
to actin and calculated as percent of the control group within each blot. All samples were run in 
triplicate and the average for each was used for the final quantification. 
 
Glycoprotein isolation  
Glycoproteins from the membrane fraction of rat cortex were purified using a Pierce 
glycoprotein isolation kit (Thermo Scientific Inc).  Glycoproteins were eluted from the column 
by heating at 95°C in 200ul SDS-PAGE buffer for 5 minutes. Glycoproteins were separated on 
12% polyacrylamide gels and transferred to PVDF membrane, which was probed with affinity-
purified anti-RGSz1 (1:100).  
 
Immunoprecipitation  
The membrane and cytosol fractions of the cortex containing 500-1000 mg of protein were pre-
cleared with 25 ml pre-washed protein G agarose beads (Invitrogen Carlsbad, CA) in total 
volume of 500 ml of IP buffer (50 mM Tris, pH 7.4, 10 mM EGTA, 100 mM NaCl, 0.5% Triton 
X-100, 20 mM NEM 1:100 protease inhibitor cocktail and 1:100 phosphatase inhibitor cocktail I 
and III) with rotation at 4°C for 1h. After centrifugation at 3000x g at 4°C for 5 min, the 
supernatant was incubated with primary antibody (4µg mouse anti-SUMO-1 (D-11), #sc-5308, 
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Santa Cruz Biotechnology; 1:50 rabbit anti-RGSz1, Biosynthesis) or 4µg IgG control and rotated 
at 4°C overnight. 50-100 ml of pre-washed protein G beads were added to each tube and rotated 
at 4°C for 2 h. Protein G beads were pelleted by centrifugation at 1000x g, at 4°C for 3 min and 
then resuspended in 0.5 ml ice cold IP buffer. After washing 3 times, the protein complexes were 
eluted in 25 ml 2X sample buffer without β-mercaptoethanol by heating at 95°C for 5 min, then 
centrifuging at 3000xg for 5 min. The supernatant was collected and stored at -80°C. Western 
blotting was performed as described above.  
 
Statistical analysis 
All data are expressed as means ± SEM. One- or two-way analysis of variance (ANOVA) and 
Student-Newman-Keuls post hoc tests were conducted using a statistical program (Statview 
version 5.0 software, SAS Institute Inc., Cary, NC). 
 
RESULTS 
GPR30 stimulation desensitizes 5-HT1AR signaling 
Our previous work has demonstrated that intra-PVN injection of EB and the GPR30 
selective agonist G-1 results in partial desensitization of 5-HT1AR signaling, as determined by 
reduced OT and ACTH release in response to 8-OH-DPAT challenge similar to EB
143
. To 
determine whether peripheral delivery of G-1 could reproduce the partial desensitization of OT 
and ACTH response, female SD rats were OVX and treated with vehicle, EB (10 µg/kg/day), 
and G-1 (2.5 and 5 mg/kg/day) for two days. 18 hours after the second injection, rats were 
challenged with (+)8-OH-DPAT (0.2 mg/kg) and plasma was collected to examine hormone 
levels. Baseline levels of plasma OT were unchanged in the treatment groups compared to 
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vehicle (Figure 4.1A). Activation of 5-HT1AR by (+)8-OH-DPAT increased plasma OT levels in 
vehicle-treated rats. The OT response was significantly reduced in the EB-treated group, 
indicating partial desensitization of the 5-HT1AR signaling pathway. The high dose of G-1 (5 
mg/kg) produced a desensitization response comparable to EB; the low dose of G-1 (2.5 mg/kg) 
also reduced the OT response, although the effect was not as robust (two-way ANOVA: main 
effect of (+)8-OH-DPAT: F(1,37) = 493.6, p <.0001; main effect of pretreatment: F(3,37) = 8.541, p 
= .0002; interaction between pretreatment and challenge: F(3,37) = 5.840, p = .0023).  
ACTH baseline response was not affected by any pre-treatment (Figure 4.1B). 
Stimulation of 5-HT1AR by (+)8-OH-DPAT increased ACTH levels in vehicle-treated rats. The 
magnitude of the ACTH response to (+)8-OH-DPAT was significantly reduced in EB-treated 
rats. Both doses of G-1 reduced ACTH significantly compared to vehicle and EB (two-way 
ANOVA: main effect of (+)8-OH-DPAT: F(1,44) = 842.6, p <.0001; main effect of pretreatment: 
F(3,44) = 7.707, p = .0003; interaction between pretreatment and challenge: F(3,44) = 7.180, p = 
.0005). Together, these data demonstrate that signaling through GPR30 is sufficient to 
desensitize the OT response to 5-HT1AR stimulation, and that control of ACTH release is even 
more sensitive to this mechanism. 
Combined fluoxetine and G-1 treatment 
 Our previous study demonstrated that combining EB treatment with the SSRI fluoxetine 
accelerated full desensitization of 5-HT1AR signaling
206
. Having shown that peripheral injection 
of G-1 for two days produced a partial desensitization response comparable to EB, we next 
investigated whether G-1 treatment would accelerate fluoxetine-induced desensitization of 5-
HT1AR signaling. OVX female rats were treated with vehicle, EB (10µg/kg/day), G-1 
(5mg/kg/day), and fluoxetine (10mg/kg/day) for two days. 18 hours after the second injection, 
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rats were challenged with (+)8-OH-DPAT (0.2mg/kg) and plasma was collected to examine 
hormone levels. Basal levels of OT were unchanged in the treatment groups compared to vehicle 
(Figure 4.2A). Activation of 5-HT1AR by (+)8-OH-DPAT significantly increased OT levels in 
the vehicle group compared to saline challenge. Two days of fluoxetine alone and EB alone 
produced comparable partial desensitization to (+)8-OH-DPAT challenge. EB and fluoxetine 
combined partially desensitized the OT response, although OT levels were significantly reduced 
only compared to fluoxetine alone and were no different from EB alone. G-1 treatment and G-
1/fluoxetine combined reduced OT levels significantly compared to vehicle treatment, but not 
compared to any other treatment (three-way ANOVA: main effect of (+)8-OH-DPAT: F(1,67) = 
888.0, p <.0001; main effect of treatment 1 (EB, G-1): F(2,67) = 8.731, p = .0004; main effect of 
treatment 2 (FLX): F(1,67) = 6.517, p = .013; interaction between treatment 1 and 2: F(2,67) = .190, 
p = .83; interaction between treatment 1 and challenge: F(2,67) = 6.896, p = .0019; interaction 
between treatment 2 and challenge: F(1,67) = 5.669, p = .0201; interaction between treatment 1, 
treatment 2, and challenge: F(2,67) = .172, p = .84). 
 ACTH baseline levels were not affected by any treatment (Figure 4.2B). Activation of 5-
HT1AR by (+)8-OH-DPAT significantly increased ACTH levels in the vehicle group compared 
to saline challenge. Two days of fluoxetine alone and EB alone produced comparable partial 
desensitization to (+)8-OH-DPAT challenge. EB and fluoxetine combined reduced ACTH 
release significantly further than either treatment alone, although as with the OT response, this 
was still only a partial desensitization response. G-1 treatment alone reduced ACTH significantly 
compared to fluoxetine alone and EB alone, and this effect was just as robust as the EB/FLX 
effect. G-1 and fluoxetine combined reduced ACTH release by the same magnitude as G-1 alone 
(three-way ANOVA: main effect of (+)8-OH-DPAT: F(1,75) = 520.6, p <.0001; main effect of 
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treatment 1 (EB, G-1): F(2,75) = 19.80, p <.0001; main effect of treatment 2 (FLX): F(1,75) = 3.652, 
p = .06; interaction between treatment 1 and 2: F(2,75) = 1.967, p = .15; interaction between 
treatment 1 and challenge: F(2,75) = 19.24, p <.0001; interaction between treatment 2 and 
challenge: F(1,75) = 3.691, p = .06; interaction between treatment 1, treatment 2, and challenge: 
F(2,75) = 2.695, p = .07). 
GPR30 stimulation alters RGSz1 isoforms in the PVN 
Our previous studies have suggested a role for RGSz1 in estradiol-induced 
desensitization of 5-HT1AR signaling
205,219,220
. The predicted molecular weight of RGSz1 is 27-
29kD; however, western blotting with an affinity-purified RGSz1 antibody reveals a ladder of 
bands with differential distribution in the cytosol and membrane fractions, and distinct patterns 
in different brain regions, which could represent different posttranslational modifications or 
alternative splice variants (Figure 4.3A). To test the hypothesis that alterations in RGSz1 
expression and posttranslational modification after GPR30 stimulation underlie estradiol-induced 
desensitization of 5-HT1AR signaling, we first examined the effect of 5mg/kg G-1 and EB 
treatment on the expression of these different RGSz1 isoforms in the PVN. 
In the cytosol fraction, both G-1 and EB treatment had dramatic effects on RGSz1 
expression. Both pretreatments increased expression of the 80kD (F(2,15) = 28, p < .0001) and 
50kD bands (F(2,17) = 5.3, p = .017) and decreased expression of the 135kD (F(2,20) = 7.7, p = 
.0033) and 40kD bands (F(2,17) = 20, p < .0001), with no change in the 35kD (F(2,17) = 1.2, p = 
.29) relative to control. G-1 pretreatment increased expression of the 90kD band relative to both 
vehicle and EB (F(2,17) = 12, p = .0006). (+)8-OH-DPAT had no effect on any of the RGSz1 
isoforms (Figure 4.3B). Because the unmodified 29kD RGSz1 band is in such low abundance 
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relative to the other isoforms, it is not easily detected with the affinity-purified antibody and thus 
was not measured in these experiments. 
In the membrane fraction, the predominant bands were at 145kD and 40kD. G-1 
treatment produced a robust increase in the 145kD band (F(2,15) = 4.4, p =.03), while EB 
treatment had no effect relative to control. Interestingly, both EB and G-1 treatment increased the 
135kD isoform (F(2,14) = 6.074, p = .01) and decreased the 80kD isoform (F(2,16) = 28, p <.0001). 
These results correspond to the changes in the cytosol, in which EB and G-1 treatment had the 
opposite effect on the respective bands. As in the cytosol, the abundance of the 40kD band was 
not affected by pretreatment (F(2,14) = .25, p = .79), and (+)8-OH-DPAT challenge had no effect 
(Figure 4.3C). 
GPR30 stimulation alters RGSz1 isoforms in the frontal cortex 
 The PVN does not contain enough protein to perform IP or subcellular fractionation. To 
determine whether the frontal cortex would be suitable to examine EB- and G-1-induced changes 
in RGSz1 isoforms via these methods, we first examined the RGSz1 expression pattern. Western 
blotting demonstrated that the frontal cortex expresses a different pattern of RGSz1 than the 
PVN. The 90kD and 80kD isoforms were abundantly expressed in frontal cortex cytosol (Figure 
4.4A) as well as membrane (Figure 4.4D). The frontal cortex did not express a 50kD band, but 
rather one of lesser molecular weight, about 45kD, and the 40kD was less relatively abundant 
than in the PVN. There was no 145kD band in the membrane fraction, but rather a more 
abundant 135kD band. In the cytosol, EB and G-1 increased the 135kD (F(2,42) = 7.071, p = .002), 
90kD (F(2,37) = 4.913, p = .01), 80kD (F(2,38) = 6.749, p = .003), 45kD (F(2,38) = 3.460, p = .04), 
and 40kD (F(2,38) = 5.783, p = .006) isoforms, but had no effect on the 35kD isoform (F(2,39) = 
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2.302, p = .11) (Figure 4.4B). Challenge with (+)8-OH-DPAT had no effect on any band 
(Figure 4.4C). 
In the membrane, EB and G-1 treatment had no effect on the 135kD isoform (F(2,33) = 
2.640, p = .11). G-1 treatment alone increased the 90kD isoform compared to vehicle and EB 
treatments (F(2,33) = 6.605, p = .004). The 80kD band was increased by G-1, but only compared 
to EB treatment (F(2,35) = 3.918, p = .03). G-1 increased the 45kD band relative to vehicle 
treatment, but not EB treatment (F(2,33) = 4.302, p = .03). Both EB and G-1 produced an increase 
in the 40kD RGSz1 band compared to vehicle treatment (F(2,36) = 5.067, p = .01) (Figure 4.4E). 
Challenge with (+)8-OH-DPAT had no effects (Figure 4.4F). 
RGSz1 isoforms have selective subcellular localization 
 To understand the functional importance of the difference RGSz1 isoforms, we examined 
their subcellular localization via gradient centrifugation to separate the subcellular organelles 
based on their density (Figure 4.5A). We used cortical tissue for these experiments because this 
region expresses the same bands as the hypothalamus (Figure 4.5A), and the PVN does not 
contain enough protein for this method. The 135kD isoform colocalized with Na
+
/K
+
ATPase, a 
plasma membrane marker. Interestingly, while the 90kD and 50kD bands did not distinctly 
colocalize with any marker, they did localize with each other and showed some overlap with the 
plasma membrane marker (Figure 4.5B). The 80kD and 35kD bands were located in the early 
endosome, as marked by EEA1 (Figure 4.5C); however, as the fractions containing the early 
endosome also contain cytosolic markers
206
, these isoforms could be located in the cytosol as 
well. Finally, the 45kD and 40kD bands were predominantly located in the ER, as determined by 
colocalization with calreticulin (Figure 4.5D). 
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 Because activated Gαz proteins are localized in DRMs of the plasma membrane
206
, the 
RGSz1 isoform that facilitates GTP-Gαz hydrolysis would need to be located in the DRM. To 
this end, we isolated DRM with Triton X-100 treatment followed by sucrose gradient 
centrifugation. DRM fractions were identified by flotillin 1 (Figure 4.6A). Interestingly, the 
135kD (Figure 4.6B) and 90kD (Figure 4.6C) proteins distributed in two distinct populations: 
one which was located in the DRM as marked by flotillin, and one which was located outside the 
DRM. The 50kD RGSz1 isoform localized entirely in the DRM (Figure 4.6C), while the 80kD 
and 40kD were not colocalized with the DRM, consistent with their location outside the plasma 
membrane (Figure 4.5).  
Posttranslational modification of RGSz1 
To determine whether the increased molecular weights of the different RGSz1 isoforms 
could be due to posttranslational modifications, we first used computer-assisted analysis of the 
RGSz1 amino acid sequence to predict potential modification sites. We found two possible sites 
for N-linked glycosylation (Center for Biological Sequence Analysis, 
http://www.cbs.dtu.dk/services/NetOGlyc/), as well as potential phosphorylation sites on several 
Ser, Thr, and Try residues (Center for Biological Sequence Analysis, 
http://www.cbs.dtu.dk/services/NetPhos/). In addition, we identified one SUMO consensus site 
via SUMOsp2.0 GPS program (http://sumosp.biocuckoo.org), and a cysteine string motif that is 
likely to be palmitoylated (http://csspalm.biocuckoo.org) (Figure 4.7A). 
To examine glycosylation of RGSz1, 1000µg of protein from the membrane fraction of 
rat cortical tissue was bound to a column containing WGA resin, then eluted from the column 
using elution buffer. Purified glycoproteins were separated using SDS-PAGE and Western 
blotting with affinity-purified anti-RGSz1 detected glycosylated RGSz1 protein. This procedure 
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identified the 135kD band as the major glycosylated isoform (Figure 4.7B); however, the yield 
was very low. Boiling the sample in SDS-PAGE buffer increased the amount of glycoproteins 
released from the WGA column, and allowed us to detect significant bands at 135kD, 80kD, and 
40kD, as well as several others (Figure 4.7C), suggesting that there are three major glycosylated 
RGSz1 protein isoforms, and the lesser bands are present in less abundant amounts or represent 
degradation products. 
To determine sumoylation of RGSz1, immunoprecipitation (IP) was performed. First, 
SUMO-1 modified proteins were immunoprecipitated from 500ug of cytosol and membrane 
fractions of rat cortical tissue and the proteins were examined via western blotting with affinity 
purified RGSz1 antibody. In the cytosol fraction, three bands were detected at 90kD, 50kD, and 
45kD. In the membrane fraction, a 135kD band was detected, as well as a major band at 90 and 
40kD (Figure 4.7D).  
Next, anti-RGSz1 antibody was used to IP RGSz1 proteins from 1000ug of cytosol and 
membrane fractions of rat cortical tissue. Western blotting with anti-SUMO2/3 revealed a ladder 
of bands, with the clearest being at 55kD, 45kD, and 35kD in the cytosol and membrane 
fractions. Although the 55kD and 45kD bands overlap with the IgG nonspecific control, the 
45kD density is much higher, indicating that it may be a real band that is the same size as the 
IgG (Figure 4.7F). Western blotting with an antibody against serine/threonine/tyrosine 
phosphorylation detected a strong band at 35kD and a lighter band at 40kD in both the cytosol 
and membrane fractions after RGSz1 IP (Figure 4.7E). 
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Figure 4.1: Effects of 10µg/kg EB, 2.5mg/kg G-1, or 5mg/kg G-1 treatment for 2 days on 
plasma OT (A) and ACTH (B) levels in response to saline or (+)8-OH-DPAT challenge in OVX 
rats. The data are presented as the mean ± SEM (n = 7-8). (*)Significantly different from saline-
challenged group with same treatment, p <.0001; (#)significantly different from (+)8-OH-DPAT-
challenged vehicle group, p <.005 by Student-Newman-Keuls post hoc test.  
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Figure 4.2: Effects of vehicle (Veh), 10µg/kg EB, 5mg/kg G-1, and/or 10mg/kg fluoxetine 
(FLX) treatment for 2 days on plasma OT (A) and ACTH (B) levels in response to saline or (+)8-
OH-DPAT challenge in OVX rats. The data are presented as the mean ± SEM (n = 7-8). 
(*)Significantly different from saline-challenged group with same treatment, p <.0001; 
(#)significantly different from (+)8-OH-DPAT-challenged vehicle group, p <.005; 
(&)significantly different from Veh/FLX group p < .05 by Student-Newman-Keuls post hoc test. 
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Figure 4.3: RGSz1 protein in the rat brain. (A) Immunoblot detection of RGSz1 expression in 
the cytosol (c) and membrane (m) fractions of the cortex (CTX), hippocampus (HPC), 
hypothalamus (HTH), and midbrain (MB) using affinity-purified anti-RGSz1 antibody. (B) 
Representative immunoblot of cytosolic RGSz1 from the PVN of rats treated with 10µg/kg EB 
or 5mg/kg G-1, with β-actin as loading control. Effect of treatment (C) and challenge (D) is 
quantified and combined from three separate immunoblots. (E) Representative immunoblot of 
RGSz1 from the membrane fraction of PVN of rats treated with 10 µk/kg EB or 5mg/kg G-1, 
with β-actin as loading control. Effect of treatment (F) or challenge (G) is quantified and 
combined from three separate immunoblots. Bands were analyzed densitometrically (integrated 
optical density, IOD). Each band was normalized to β-actin and expressed as percent of control 
(vehicle or saline). Data are expressed as mean ± SEM (n = 4). (*) Significantly different from 
vehicle control; (#) significantly different from EB, p <.05 by Student-Newman-Keuls post hoc 
test. 
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Figure 4.4: RGSz1 protein in the frontal cortex. (A) Representative immunoblot of cytosolic 
RGSz1 from the frontal cortex of rats treated with 10µg/kg EB or 5mg/kg G-1, with β-actin as 
loading control. Effect of treatment (B) and challenge (C) is quantified and combined from three 
separate immunoblots. (D) Representative immunoblot of RGSz1 from the membrane fraction of 
frontal cortex of rats treated with 10 µk/kg EB or 5mg/kg G-1, with β-actin as loading control. 
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Effect of treatment (E) or challenge (F) is quantified and combined from three separate 
immunoblots. Bands were analyzed densitometrically (integrated optical density, IOD). Each 
band was normalized to β-actin and expressed as percent of control (vehicle or saline). Data are 
expressed as mean ± SEM (n = 8). (*) Significantly different from vehicle control; (#) 
significantly different from EB, p <.05 by Student-Newman-Keuls post hoc test. 
 
 
Figure 4.5: Subcellular distribution of RGSz1 protein in subcellular fractions from 
discontinuous iodixanol gradient centrifugation prepared with rat cortex. Representative 
immunoblot is shown in (A). Graphical representations show the colocalization of RGSz1 with 
plasma membrane marker, Na
+
/K
+
ATPase (B); early endosome marker EEA1 (C); and ER 
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marker calreticulin (D). Data are expressed as % of peak across fractions, and represent the 
average of three experiments. 
 
Figure 4.6: Distribution of RGSz1 protein in sucrose gradient fractions of Triton X-100 treated 
cortex homogenates. (A) A representative immunoblot is shown. Fractions containing the DRM 
were identified by the DRM marker flotillin. Total: Triton X-100 treatment without sucrose 
gradient centrifugation. Graphical representations show the colocalization of RGSz1 with 
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flotillin (B and C). Data are expressed as % of peak across fractions, and represent the average of 
three experiments. 
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Figure 4.7: Posttranslational modifications of RGSz1. (A) Rat RGSz1 primary amino acid 
sequence. Predicted glycosylation sites are underlined and bolded; predicted sumoylation site is 
bolded; predicted palmitoylation motif is underlined and italicized; predicted phosphorylation 
sites are shaded in gray. (B) RGSz1 immunoblot of glycoprotein isolated from cortical 
membrane fraction. Input: sample before isolation. FT: column flow-through. GPE: eluted 
glycoproteins. (C) RGSz1 immunoblot of isolated glycoprotein eluted from column by boiling in 
SDS-PAGE sample buffer. CE: control eluate (lectin column without protein added). CFT: 
control flow-through. (D) Immunoprecipitation (IP) of SUMO-1 and immunoblot detection of 
RGSz1 in cytosol and membrane fractions of cortex. Input: sample before IP. IgG: mouse 
immunoglobin G control. IB: immunoblot. (E) IP of phosphorylated RGSz1 in cytosol and 
membrane fractions of cortex. IgG: rabbit immunoglobin G control. (F) IP of RGSz1 and 
immunoblot detection of SUMO2/3 in cytosol and membrane fractions of cortex. IgG: rabbit 
immunoglobin G control. (G) Summary of RGSz1 isoform characterization. ↑: increased 
expression after treatment. ↓: decreased expression after treatment. X: no change in expression 
after treatment. Bands that were unmeasured in the PVN are left unmarked. 
 
DISCUSSION 
 The most consistent biomarker in depressed patients is increased HPA axis activity
85
, and 
normalization of HPA axis function is associated with successful antidepressant treatment
84
. We 
can model HPA axis activity in rats through neuroendocrine challenge, in which the HPA axis is 
activated by acute injection of the selective 5-HT1AR agonist (+)8-OH-DPAT. Reduction in the 
magnitude of OT and ACTH hormone response to (+)8-OH-DPAT demonstrates desensitization 
of 5-HT1AR signaling in the PVN
190,236
, which is related to the therapeutic effects of SSRIs
187,188
. 
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Two days of EB treatment produces a partial desensitization of 5-HT1AR signaling. We 
previously reported that this effect is mediated by GPR30, as knockdown of GPR30 expression 
prevents EB-induced desensitization, and intra-PVN injection of G-1 produces a partial 
desensitization in the hormone response to (+)8-OH-DPAT
143,220
. However, the ability of 
systemically-delivered G-1 to affect central 5-HT1AR signaling in rats had not yet been tested. In 
the present study, we administered 10µg/kg EB, 2.5mg/kg G-1, and 5mg/kg G-1 via 
subcutaneous injection for two days, then measured the OT and ACTH response to (+)8-OH-
DPAT challenge. The results demonstrated that systemic G-1 treatment had a dose-dependent 
effect on OT release, with the higher dose reducing OT release by the same magnitude as EB. 
This dose-dependent effect of G-1 on OT release is consistent with our previous study using 
injections of G-1 directly into the PVN
143
. The ACTH response did not show a dose-dependent 
effect with systemic injections; consistent with our previous intra-PVN results, both doses of G-1 
produced a similar reduction of plasma ACTH
143
, which was even more robust than EB 
treatment. Increasing the dose of EB or extending the length of treatment does not further reduce 
the hormone response to (+)8-OH-DPAT
205,206
. The results here suggest that G-1 is more 
effective than EB in desensitizing 5-HT1AR signaling, and it is possible that higher doses may 
attenuate the OT response even further.  
In this experiment, we did not see the same full desensitization in the hormone responses 
after combined EB and fluoxetine treatment as we saw previously
206
. However, EB alone and G-
1 alone had the same effects on reduced hormone release as in the first experiment in this study 
(Figure 4.1): EB produced a partial desensitization in both OT and ACTH responses, 5mg/kg G-
1 produced a partial desensitization in the OT response that was not significantly different than 
EB, and 5mg/kg G-1 reduced the ACTH response to (+)8-OH-DPAT significantly further than 
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EB alone. This suggests that the effects of fluoxetine to desensitize 5-HT1AR signaling did not 
have as robust an effect as previously. While two days of fluoxetine did produce a reduction in 
the hormone response to (+)8-OH-DPAT, it was very slight. A control group of seven-day 
fluoxetine treatment should be included to determine whether full desensitization with fluoxetine 
alone could be achieved, or if there was some problem with the drug preparation. However, these 
results confirm the differential effects of EB and G-1 on OT and ACTH release, and suggest that 
G-1 treatment is more potent than EB in accelerating fluoxetine-induced desensitization of 5-
HT1AR signaling.. 
The difference in the OT and ACTH responses to 5-HT1AR stimulation after G-1 and EB 
treatment is notable. There is a partial estrogen response element in the promoter region of the 
CRF gene, and estradiol treatment has been shown to increase CRF mRNA and protein 
expression, as well as AVP mRNA, likely through an ERβ-mediated mechanism. In addition, 
data suggest that estradiol may interact directly, rather than through a receptor, with CRF and 
AVP to regulate the HPA axis
117
. This could explain the inconsistent data regarding EB-induced 
attenuation of ACTH response to (+)8-OH-DPAT. Selective stimulation of GPR30 with G-1 
avoids an EB-induced increase in CRF, thus blunting the ACTH response. CRF action is 
regulated by CRF binding protein, which is higher in females than males and is positively 
regulated by ovarian hormones
286
. Increased expression of CRF binding protein via GPR30 
could therefore serve to suppress ACTH release.  In addition, circulating AVP from the SON 
may induce ACTH release from the pituitary
287
. GPR30 is highly expressed in the SON, and 
stimulation by G-1 may regulate AVP in these cells. Further work is needed to pursue these 
possibilities. 
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 It is clear from the present study that signaling through GPR30 produces dramatic 
changes in expression and posttranslational modification of RGSz1. Not only is expression of 
RGSz1 isoforms brain-region-specific, with the hypothalamus expressing fewer bands than the 
cortex or midbrain, but changes in RGSz1 protein after EB or G-1 treatment are also different 
depending on the region. Previous work in our laboratory found that EB treatment produced a 
decrease in the 40kD RGSz1 isoform in the hippocampus but no change in the amygdala. 
Furthermore, a decrease of the 40kD band was observed in the PVN after EB treatment but this 
band was increased in the rest of the hypothalamus
205
. The disparity between RGSz1 expression 
in the frontal cortex versus PVN again suggests that addition or subtraction of posttranslational 
modification is controlled locally, most likely due to the types of estrogen receptors expressed in 
each region. Unlike in the PVN, G-1 treatment and not EB altered RGSz1 isoform expression in 
the membrane fraction. This reinforces the evidence from the PVN that RGSz1 modification is 
regulated by GPR30 signaling. EB signaling through ERα and ERβ often has opposing effects, 
so selectively activating GPR30 would preclude any contrary signaling through other estrogen 
receptors. 
 Investigation of RGSz1 posttranslational modification identified sumoylation, 
glycosylation, and phosphorylation of RGSz1 isoforms. Sumoylation is the covalent addition of a 
small ubiquitin-related modifier (SUMO) to a protein. Sumoylation affects a variety of cellular 
processes including subcellular localization and transcriptional regulation, but it is thought that 
its primary function is to control protein-protein interactions. Vertebrates express three SUMO 
isoforms (SUMO1 and the nearly identical SUMO2/3). SUMO2/3 contains a SUMO consensus 
sequence, and can form poly-SUMO chains via isopeptide linkages; SUMO1 does not contain a 
consensus site and sumoylation of a poly-SUMO chain with SUMO1 can thus serve to terminate 
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the chain
288,289
. RGSz1 contains a SUMO consensus sequence, as well as a SUMO-interacting 
motif (SIM – amino acids 173-176) which allows for the non-covalent interaction of a protein 
with SUMO. The present study demonstrated that the 135kD, 90kD, and 50kD RGSz1 isoforms 
are sumoylated with SUMO1 and located in the DRM. Furthermore, treatment with EB and G-1 
resulted in an increase in the 135kD RGSz1 in the membrane, with a corresponding decrease in 
the non-sumoylated 80kD isoform. We observed a ladder pattern of SUMO2/3 immunoreactivity 
after RGSz1 IP, which suggests chains of SUMO2/3. Addition of a SUMO1 molecule as a cap to 
a poly-SUMO2/3 chain could account for the increase in apparent molecular weight from 80kD 
to 135kD; thus sumoylation may be acting as a molecular switch to increase RGSz1 in the DRM 
of the plasma membrane to regulate Gαz signaling. Our previous study found that sumoylated 
Gαz is located in the DRM, and is decreased by EB treatment. Since the DRM is the location of 
active GPCR signaling proteins, the increase in RGSz1 in the DRM would reduce the activity of 
Gαz signaling by hydrolyzing the activated GTP-bound Gαz to inactive GDP-bound Gαz. The 
EB and G-1 induced increase of DRM-localized RGSz1 together with the EB-induced decrease 
of DRM-localized Gαz would reduce 5-HT1AR signaling.  
 We found that the 35kD, and possibly the 50kD, RGSz1 isoforms are phosphorylated. 
Phosphorylation is critical in the control of many cellular pathways, and may be a regulator of 
non-nuclear sumoylation as well
289
. Depending on the substrate, the negative charge of a 
phosphate group can enhance or inhibit sumoylation
290,291
. Additionally, phosphorylation of a 
serine residue adjacent to the SUMO consensus sequence acts as a switch to favor sumoylation 
over acetylation
292
. While RGSz1 does not have the precise motif that serves as a SUMO-acetyl 
switch, there is a serine residue (S159) adjacent to the SUMO consensus site that, if 
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phosphorylated, could facilitate sumoylation. S159 is located within a predicted N-linked 
glycosylation site, and could thus also function to inhibit or facilitate RGSz1 glycosylation.  
 Protein glycosylation plays an important role in protein structure, signal transduction, 
cell-cell interactions, and hormone action
293-295
. Addition and editing of carbohydrate units to 
proteins occurs in the ER and Golgi apparatus. Here, we found that a major glycosylated form of 
RGSz1, at 40kD, localized to the ER. The RGSz1 proteins of greater molecular weights than 
40kD are also glycosylated, suggesting that the 40kD band, which is the most abundant of the 
RGSz1 isoforms, may serve as a pool from which, once glycosylated, other modifications such 
as sumoylation or palmitoylation can be added or removed, thus regulating RGSz1 localization 
and function.  
 The RGSz1 primary amino acid sequence contains a conserved cysteine string motif 
which is predicted to be palmitoylated. Palmitoylation occurs at the membrane and has a 
functional effect on membrane attachment and targeting, microdomain localization, and protein 
orientation at the membrane. Several RGS proteins are known to undergo palmitoylation, 
including RGSZ family member GAIP
296
. Palmitoylation of RGS4 and RGS16 is necessary for 
their targeting to DRM and ability to regulate G protein signaling, as well as endosomal 
trafficking
69,297
. We found that the 80kD RGSz1 isoform colocalized with the early endosome 
marker EEA1, and that EB and G-1 treatment greatly increased its expression in the cytosol. This 
suggests that endosomal trafficking of RGSz1 could occur from the Golgi to the plasma 
membrane, where palmitoylation could then stabilize the 90kD and 135kD RGSz1 isoforms in 
the DRM. 
Interestingly, we found that while EB and G-1 treatment produced comparable changes in 
most of the RGSz1 bands measured in the PVN, only G-1 affected the 145kD and 90kD bands in 
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the membrane and cytosol, respectively, producing a dramatic increase relative to control and EB 
treatment. That their expression was so markedly affected by G-1 treatment suggests that these 
isoforms may be of particular importance to GPR30-mediated desensitization of 5-HT1AR 
signaling, and could contribute to the apparent sensitivity of the ACTH response to G-1 over EB 
treatment; ACTH release is under the control of CRF, and while the mechanism by which Gαz 
mediates CRF release is still unclear, it could be particularly susceptible to regulation by the 
145kD RGSz1 isoform. Localization of the 90kD isoform in the DRM supports a significant role 
for this isoform in the regulation of Gαz. The 145kD band appears to be specific to the 
membrane fraction of the PVN: it is not seen in the cortex, hippocampus, amygdala, or even the 
other regions of the hypothalamus. The PVN does not contain enough protein to perform 
immunoprecipitation of RGSz1, so characterization of this isoform is difficult; however, its 
localization to the membrane suggests a role for palmitoylation, glycosylation, or acylation.  
RGSz1 is a product of the RGS20 gene (NM_001127495.1), which also codes for Ret-
RGS. RGS20 spans seven exons, five of which code for RGSz1. Mouse and human RGSz1 
mRNA contains multiple possible start codons, which may contribute to the heterogeneity of 
protein size in these species
298
. Rat mRNA, however, only contains one start codon upstream of 
the known transcription start site, and there is an in-frame stop codon 55 base pairs later. 
Therefore, alternate transcription of RGSz1 is not likely to produce the higher molecular weight 
proteins that we see in the rat brain. Little is known of potential splice variants of RGSz1; there 
are two introns in the RGS domain, and alternative splicing could give rise to different protein 
isoforms with different levels of GAP activity or affinities for Gαz. Further investigation into this 
possibility is required. 
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In conclusion, the present results demonstrate for the first time that two-day treatment via 
peripheral delivery of the selective GPR30 agonist G-1 produces desensitization of 5-HT1AR 
signaling. This is significant for potential translation to preclinical and clinical studies, as 
peripheral injections are more feasible than intra-PVN delivery. We also showed that RGSz1 in 
the rat brain is posttranslationally modified, and that EB and G-1 treatment altered these 
modifications in the PVN. RGSz1 posttranslational modification therefore likely has a significant 
functional impact on RGSz1 activity and regulation of Gαz signaling in the PVN. Of particular 
importance is the stabilization of RGSz1 in the DRM of the plasma membrane, via sumoylation 
and glycosylation, where it can physically interact with activated Gαz and shut off 5-HT1AR 
downstream signaling, thus reducing HPA axis activity. This suggests a new mechanism by 
which EB accelerates SSRI-induced desensitization of 5-HT1AR signaling. Because estrogen 
therapy is associated with increased risk for breast cancer, heart disease, and stroke
207,209,284
, it is 
important to identify more selective therapeutic adjuvants for SSRI treatment of depression. Our 
results provide evidence that targeting GPR30 and RGSz1 may provide a selective mechanism 
for the acceleration of SSRI therapeutic effects. 
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CHAPTER 5: GENERAL CONCLUSIONS 
 
REVIEW OF RESULTS AND SIGNIFICANCE 
 Acute treatment with an SSRI such as fluoxetine blocks serotonin transporters and 
increases serotonergic transmission at both pre- and post-synaptic sites. Stimulation of pre-
synaptic, inhibitory 5-HT1A autoreceptors decreases serotonergic tone transiently; however, 
continued stimulation of post-synaptic 5-HT1AR would potentiate HPA axis activity. After 
chronic SSRI treatment, the autoreceptors in the DRN desensitize, which increases serotonergic 
tone in target regions such as the PVN. This increase in serotonin release, combined with 
continued SSRI-induced prevention of synaptic clearance, would increase post-synaptic 5-
HT1AR signaling until these receptors desensitize. The time that it takes for desensitization of 
both autoreceptor and post-synaptic receptor signaling to occur likely underlies the therapeutic 
lag associated with SSRI treatment
201-203,299
. The results presented here, when compared with the 
findings of other studies investigating the molecular effects SSRIs and estradiol treatment, 
suggest three general ways in which these two treatments promote desensitization of 5-HT1AR 
signaling: 1) decreased 5-HT1AR protein, 2) decreased active Gαz, and 3) altered RGSz1 
expression. 
In chapter three, we identified two important EB-induced changes in the hypothalamic 
PVN 5-HT1AR signaling pathway: decreased levels of 5-HT1AR protein, and increased levels of 
two isoforms of RGSz1 protein and RGSz1 mRNA. These molecular changes accompanied EB-
induced partial desensitization of 5-HT1AR signaling as measured by reduced OT and ACTH 
release after challenge with the selective 5-HT1AR agonist (+)8-OH-DPAT. We next used a 
recombinant adenovirus containing siRNAs against GPR30 to knockdown GPR30 protein 
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expression in the PVN by about 32%. This reduction was enough to prevent the reduction of the 
hormone response to (+)8-OH-DPAT, demonstrating that GPR30 is necessary for EB-induced 
desensitization of 5-HT1AR signaling. 
The results that only a partial reduction in GPR30 protein levels (<40%) was successful 
in preventing EB-induced desensitization of 5-HT1AR signaling suggests that a high level of 
PVN GPR30 expression is necessary for this effect of EB. This is most likely due to EB 
activation of ERα and ERβ in addition to GPR30. EB stimulation may produce a 
counterbalancing effect through ERα expressed on GABAergic neurons in the periventricular 
regions of the hypothalamus that project to the PVN. 17β-estradiol treatment increases CRF 
mRNA and protein expression, as well as AVP mRNA expression, compared to controls
117
; if 
these effects are mediated through ERα/β and not GPR30, G-1 treatment would have a stronger 
effect than EB treatment. The findings in chapter four that G-1 treatment reduces ACTH release 
even further than EB supports this idea. Additionally, 5-HT2A/CR in the PVN colocalize with 
CRF, and regulate CRF and AVP, and thus ACTH, release
93,300
. There is evidence for estradiol 
modulation of 5-HT2AR: ovariectomy decreased 5-HT2AR mRNA in the PVN, and one month 
treatment of 17β-estradiol increased 5-HT2AR binding sites while decreasing 5-HT1AR binding 
sites in the frontal cortex of ovariectomized monkeys
301
. Added to the finding that ACTH release 
is more sensitive to G-1 treatment than OT, these results suggest a complex system of receptor 
interactions by which EB attenuates the hypothalamic-pituitary endocrine systems. 
In chapter four, we demonstrated that two day EB and G-1 treatment produced robust 
alterations in RGSz1 protein expression in the PVN that accompanied EB- and G-1-induced 
desensitization of 5-HT1AR signaling. We also characterized the posttranslational modifications 
and subcellular localization of these RGSz1 isoforms. A 145kD RGSz1 band, which was 
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detectable only in the membrane fraction of the PVN, was increased by G-1, and not EB 
treatment, as well as a 90kD band in the cytosol; these changes may be important for the 
difference in EB versus G-1 treatment effects on ACTH release after 5-HT1AR stimulation. 
Significantly, the 135kD isoform was glycosylated and sumoylated and localized to the DRM of 
the plasma membrane. EB and G-1 treatment decreased the 135kD protein in the cytosol and 
increased it in the membrane. Increased RGSz1 in the DRM would function to increase GAP-
accelerated hydrolysis of GTP-bound Gαz, thus reducing Gαz downstream effector activation 
and producing desensitization of 5-HT1AR signaling. 
Previous results demonstrated that EB and fluoxetine have a synergistic effect on 
desensitization of 5-HT1AR signaling
206
. Fluoxetine has been shown to decrease circulating 
estradiol in intact animals
302,303
; this could in part contribute to the therapeutic lag of fluoxetine 
treatment. Additionally, short-term (two day) treatment with fluoxetine increased 5-HT1AR 
protein in the PVN, an effect that was blocked by EB treatment
206
. Indeed, in chapter three we 
found a decrease in 5-HT1AR protein after EB treatment, and further evidence shows that EB 
treatment decreases density of 5-HT1AR binding sites
169,301
, likely by increasing sumoylation-
mediated internalization of 5-HT1AR
304
. Two-day EB treatment also increases 5-HT1AR mRNA, 
which could explain why longer than two days or higher dose does not further desensitize 5-
HT1AR signaling
205,220
. 
In addition to decreased 5-HT1AR availability, a reduction in Gαz protein levels would 
have the functional effect of reducing hormone release after 5-HT1AR stimulation. While some 
studies report decreased Gαz after EB treatment
204
 and some report no change
219,220
, levels of 
Gαz protein have been shown to be decreased following chronic fluoxetine treatment
191
. The 
RGS-Rz subfamily binds with the dileucine-rich region of GAIP interacting protein N terminus 
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(GIPN), a putative E3 ubiquitin ligase that links RGS-Rz proteins with Gαi3 degradation; GAIP 
functions as an adaptor that binds to Gα subunits through the RGS domain and to GIPN through 
a cysteine string motif
305
. While this has not been demonstrated for RGSz1 and Gαz, RGSz1 
possesses the same cysteine string motif and could potentially interact with GIPN to the effect of 
promoting ubiquitination and degradation of Gαz. In chapter four, we found that 80kD and 50kD 
RGsz1 isoforms were increased in the cytosol after EB and G-1 treatment, and that the 80kD 
isoform was associated with the early endosome; depalmitoylation of membrane-associated 
RGSz1 could promote trafficking of Gαz-bound RGSz1 from the plasma membrane to the early 
endosome and subsequent ubiquitination and degradation of Gαz. This could explain the 
decrease in Gαz sometimes seen after EB treatment
204
, and contribute to EB-induced acceleration 
of fluoxetine-induced 5-HT1AR signaling. 
Another important factor in desensitization 5-HT1AR signaling is the regulation of Gαz 
signaling, apart from its protein expression. Phosphorylation and palmitoylation of Gαz inhibits 
RGSz1 GAP activity and potentiates Gαz downstream signaling
79,80,306,307
. Gαz is 
phosphorylated at two sites by PKC and at one of those sites by PAK, which could allow 
regulation by several signaling pathways
67
. One such pathway is the activation of and subsequent 
phosphorylation by GSK3β. GSK3β is inhibited by phosphorylation and is a target of the mood 
stabilizer lithium. Acute and chronic treatment with fluoxetine and imipramine, respectively, 
increased the phosphorylated (inactive) form of GSK3β, an effect which was associated with 
antidepressant-like behavior in the forced swim task (FST)
308,309
. Inhibition or deficiency of 
GSK3β also decreases immobility in the FST, suggesting that inactivation of GSK3β, and 
therefore decreased phosphorylation of Gαz and increased RGSz1-Gαz interaction, is important 
in the antidepressant effects of fluoxetine
310
. 
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 Additionally, stimulation of 5-HT1AR by 8-OH-DPAT increased phosphorylation of 
GSK3β, an effect mediated by Gαi and Akt signaling that was prevented by 5-HT1AR antagonist 
WAY 100,635
311
. This suggests a negative feedback mechanism whereby 5-HT1AR signaling 
through Gαi has the effect of decreasing signaling through Gαz by preventing GSK3β-mediated 
phosphorylation of Gαz. Stimulation of 5-HT2AR had the opposite effect of activating GSK3β
308
, 
indicating that serotonergic regulation of GSK3β depends on the balance between the two 
receptor subtypes. 5-HT2AR activation by fluoxetine could therefore counterbalance a 5-HT1AR-
mediated increase in GSK3β phosphorylation, thus delaying the onset of therapeutic action. 
 GPR30 signaling through the βγ subunit transactivates epidermal growth factor receptor 
(EGFR) signal transduction cascades
312
, including activation of PKC. While PKC phosphorylates 
Gαz, inhibiting GAP activity, it also phosphorylates GSK3β. Increased GSK3β phosphorylation 
via GPR30-EGFR activation in addition to EB-induced increases in RGSz1 could tip the balance 
in favor of inactivated Gαz, thus contributing to desensitization of 5-HT1AR signaling. GPR30-
induced phosphorylation of GSK3β has not been investigated directly, but EGFR can promote 
GSK3β inactivation through an Akt-mediated pathway. Interestingly, ICI182780, which is an 
antagonist for ERα/β but an agonist for GPR30
312
, induced GSK3β phosphorylation in the mouse 
uterus
313
 and 17β-estradiol increased Akt phosphorylation of GSK3β in the caudate nucleus and 
putamen of ovariectomized monkeys
314
. These results suggest a role for GPR30 mediation of 
GSK3β, and thus regulation of Gαz activity. 
 Activation of 5-HT1AR by 8-OH-DPAT in transfected COS cells promoted proteosomal 
degradation of recombinant RGSz1 via a Gαi/o-mediated pathway
315
. Fluoxetine-induced 
increase in serotonin transmission could thus reduce RGSz1 levels and potentiate Gαz signaling. 
A previous study reported that chronic fluoxetine treatment had no effect on unmodified RGSz1 
 105 
levels in vivo, but two days of EB treatment increased expression
219
. In the present studies, we 
found that the 35kD, and possibly 50kD, RGSz1 isoforms are phosphorylated, and the 50kD 
isoform was increased by EB and G-1 treatment. Phosphorylation by a MAP kinase Fus3p 
increased the half life of Sst2p, a yeast RGS protein
316
, and ubiquitin-directed proteolysis of 
RGS7 was prevented by activation of MAP kinase p38
317
. GPR30 activation of MAP kinase 
signaling cascades could thus promote the phosphorylation of RGSz1, leading to increased 
stability and protection against fluoxetine-induced degradation. 
 
Table 5.1: Comparison of fluoxetine and estradiol effects on 5-HT1AR signaling. 
 
LIMITATIONS OF THE PRESENT STUDIES 
 One major limitation of the present studies is the small size, and thus low protein yield, of 
the PVN. Both fluoxetine and EB treatments have differential effects throughout the brain; 
although we were able to use cortical protein to characterize RGSz1 isoforms, we could not use 
these same methods with protein from the PVN, and so must assume that the posttranslational 
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modifications seen in the cortex are the same in PVN RGSz1 proteins of the same size. For the 
same reason, we were unable to directly establish a causal relationship between alteration of 
RGSz1 posttranslational modification and G-1-induced desensitization of 5-HT1AR signaling. 
Furthermore, cells transfected with RGSz1 cloned from the rat PVN only express the unmodified 
27kD RGSz1 protein, and further work is required to directly demonstrate posttranslational 
modification of RGSz1. 
 Another limitation is the RGSz1 antibody used. Rabbit-anti-RGSz1 was produced and 
affinity purified by Biosynthesis, and it was this antibody that was used in the earlier 
experiments
205
 (chapter three). Using this antibody, we were able to detect a 55kD RGSz1 
isoform in the PVN that was affected by EB treatment. However, this antibody also showed a 
large amount of nonspecific binding. To reduce the background noise, we affinity-purified the 
anti-RGSz1 antibody again, and while this method substantially reduced nonspecific binding, it 
also decreased the antibody binding to the 55kD RGSz1 isoform. This isoform is more abundant 
in other brain regions, such as the cortex, and can thus still be detected on western blots, but not 
in the PVN. Similarly, the 27kD unmodified RGSz1 protein is much harder to detect with the 
purified antibody, and could not be measured in the experiments in chapter four. 
 Also lacking in these studies is a behavioral model for depression. The FST is one of the 
most common behavioral tests for depressive-like drug effects in animal models; however, this 
test and others (such as novelty-suppressed feeding test, tail suspension test, learned 
helplessness, and inescapable stress models) produce a generalized stress in which the HPA axis 
is activated via 5-HT1AR, 5-HT1B, 5-HT2A/CR, and 5-HT7R, making it difficult to tease out 
receptor-specific effects. EB acts as an antidepressant in the FST, as does acute fluoxetine
318
 and 
5-HT1AR agonists such as azapirones and 8-OH-DPAT
24
; the increased stress hormone levels 
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induced by acute fluoxetine and 5-HT1AR agonists is likely what produces the animals’ increased 
activity in these behavioral measures. In our model, we are using decreased stress hormone 
levels as the measure of effective antidepressant treatment. In the clinic, increased stress 
hormone levels, namely ACTH and cortisol, is an important biomarker in clinical depression, 
and normalization of HPA axis activity correlates with successful antidepressant treatment. 
Therefore our neuroendocrine model can be used to demonstrate functional changes in PVN 5-
HT1AR and HPA axis activity after EB and G-1 treatment and represent what can be measured in 
a clinical setting. 
 
FUTURE STUDIES 
To directly show that RGSz1 is posttranslationally modified, and that the modifications 
are altered by EB and G-1 treatment, further work should be done to express RGSz1 in cells 
along with the appropriate cellular machinery for sumoylation, glycosylation, phosphorylation, 
and palmitoylation. Once RGSz1 posttranslational modifications can be induced in cell culture, 
site-directed mutagenesis of the posttranslational modification sites predicted in this study could 
be performed to provide further evidence for important roles for RGSz1 posttranslational 
modification. Additionally, mass spectrometry analysis of the RGSz1 isoforms detected via 
western blotting could confirm that the proteins detected were indeed RGSz1, especially given 
the nonspecific binding demonstrated by the RGSz1 antibody. Further, genetic approaches of 
knocking down or overexpressing RGSz1 in the PVN in vivo will be important to directly 
demonstrate the necessity of RGSz1 in EB-induced desensitization of 5-HT1AR signaling. 
Selectively altering specific RGSz1 posttranslational modifications, such as sumoylation or 
glycosylation, in vivo will be more complicated, as these modifications are vital in a large 
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number of cellular processes. However, administration of MAP kinase inhibitors, for example, to 
target GPR30-EGFR signaling pathways could help identify the specific mechanisms involved in 
the regulation of RGSz1 posttranslational modification. 
One of the most translationally-significant findings in these studies is that systemic 
delivery of G-1 produced desensitization of 5-HT1AR signaling. Using peripheral, rather than 
intra-PVN, injections make G-1 treatment feasible for use in clinical trials. Selectively activating 
GPR30 over ERα and ERβ produces a more robust desensitization of the ACTH response to 
(+)8-OH-DPAT, which may translate directly to clinical findings that depressed patients 
demonstrate elevated CRF and cortisol levels. Using G-1, rather than estrogens, as an adjunctive 
to SSRI treatment of depression may decrease the side effects and increased risk for disease that 
are associated with estrogen therapy. EB treatment requires at least two days to induce 
desensitization of 5-HT1AR signaling, but increasing the dose from 10µg/kg or extending the 
length of treatment does not reduced hormone release any further. In these experiments, we only 
examined the effects of G-1 at one time point. One of the most important molecular changes 
induced by G-1 was the alteration of RGSz1 posttranslational modification and changes in 
subcellular localization; these types of changes may not necessarily require changes in 
transcriptional activity, and so could possibly be produced in a much shorter time frame than two 
days. Therefore, it will be important to establish a time course for G-1 treatment. Because we 
saw a dose-dependent effect of G-1 treatment on ACTH release in both neuroendocrine 
experiments, a dose response curve should be established as well. Lower doses of G-1 may be 
just as effective as EB to attenuate the ACTH response to (+)8-OH-DPAT, and doses higher than 
5 mg/kg may attenuate the response even further, leading to increased acceleration of fluoxetine-
induced desensitization of 5-HT1AR signaling or possibly even full desensitization due to G-1 
 109 
alone. That G-1, not EB, had such a distinct effect on ACTH and not OT levels suggests a 
mechanism in which GPR30 signaling is effecting expression or release of CRF and AVP, as 
discussed in chapter four. It will therefore be important to examine possible changes in these 
compounds after G-1 treatment. Finally, repeating the G-1 and fluoxetine combined treatment 
experiment from chapter four with the best time course and dose of G-1, and better controls for 
fluoxetine, will be important to directly demonstrate whether G-1 treatment works synergistically 
with fluoxetine to improve the therapeutic efficacy of SSRIs. 
 
CONCLUSIONS 
 The data presented here support the hypotheses that GPR30 is both necessary and 
sufficient for estradiol-induced desensitization of 5-HT1AR signaling, and that GPR30 
stimulation mediates alterations in RGSz1 expression and posttranslational modification. 
Alterations in RGSz1, particularly in DRM-localized sumoylated and glycosylated RGSz1, could 
increase RGSz1 acceleration of Gαz-GTP hydrolysis, thus reducing Gαz signaling and 5-HT1AR-
mediated hormone release. These results suggest a mechanism by which estradiol accelerates 
fluoxetine-induced desensitization of 5-HT1AR signaling, as well as identify GPR30 and RGSz1 
as potential novel targets for the improved treatment of depression. 
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